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RESUMO 
 
A doença do enxerto contra o hospedeiro crônica (DECHc) é um processo 
inflamatório aloimune o qual resulta da resposta celular (células T) do doador contra o 
receptor em pacientes tratados pelo transplante de células progenitoras hematopoiéticas 
(TCTH). Os órgãos mais afetados são pele, mucosa oral, glândulas salivares e fígado. O 
objetivo deste trabalho foi avaliar os achados histopatológicos das glândulas salivares 
menores (GSM) e fígado dos pacientes afetados pela DECHc, comparando-os entre si, com 
as amostras destes órgãos de pacientes que não desenvolveram DECHc pós TCTH e com 
pacientes que não foram tratados pelo TCTH. Amostras de GSM e fígado de pacientes 
tratados por TCTH mieloablativo, de doadores aparentados com HLA idêntico, entre 1994 
e 2006, foram analisadas. Cinquenta e sete pacientes foram selecionados, sendo 36 com 
DECHc oral e hepática e 21 sem DECH. O diagnóstico de DECHc foi definido por critérios 
clínicos (extensa/localizada), laboratoriais e de seguimento. Amostras sem alterações de 
pacientes não transplantados também foram avaliadas (19 de GSM e 20 de fígado). Os 
espécimes foram corados em hematoxilina e eosina, ácido periódico de Schiff (PAS), 
Tricrômio de Masson, Reticulina e Perls e tratados pela técnica de imuno-histoquímica para 
CD45, CD45RO, CD68, CD4, CD8, CD138 e AE1/AE3. Os critérios definidos pela 
classificação proposta pelo grupo de trabalho em histopatologia da reunião de consenso do 
National Institutes of Health (NIH) foram empregados para a avaliação de todas as 
amostras de ambos os órgãos. Nos espécimes corados pelo PAS, foi tomada a medida da 
área acinar das GSM, em imagens digitalizadas. No fígado de pacientes que desenvolveram 
DECH, foi observado aumento estatisticamente significante do número de células 
imunomarcadas para CD8 e CD45RO, quando comparado ao dos outros 2 grupos. Os 
resultados da análise dos critérios do NIH no fígado mostraram que 12 deles apresentaram 
correlação significante com o diagnóstico da DECH hepática e sete com a elevação sérica 
dos níveis de, pelo menos, uma enzima hepática e/ou bilirrubina. Foi também observado 
que o número de células CD8
+
 e CD45
+
/mm
2
 nas GSM, mostrava valor preditivo para o 
diagnóstico de DECH no fígado. O número relativo de células CD45
+
, CD4
+
 e CD8
+
 nas 
GSM se correlacionava com o das mesmas subpopulações celulares do fígado.  Nas 
amostras de GSM foi observada diferença significante no número de células imuno-
 ix 
marcadas para CD4, CD8, CD45 e CD45RO, quando os dois grupos de pacientes 
transplantados foram comparados entre si. Porém, para o CD68 e CD138, não houve 
diferenças.  A área acinar PAS
+
 das GSM mostrou diferença significante entre os três 
grupos. As alterações das GSM refletem aquelas do fígado, nos pacientes com a DECHc. 
Adicionalmente, o aumento do número de células CD45
+
 e a diminuição de células CD8
+
 
nas GSM são preditivos do diagnóstico de DECH no fígado. Como as amostras de 
glândulas salivares menores podem ser obtidas com mais facilidade do que as do fígado, 
este achado pode ser útil na estimativa do dano hepático, em pacientes transplantados, com 
alterações enzimáticas sugestivas do diagnóstico de DECH. Uma vez que o número de 
linfócitos nas GSM de pacientes transplantados que não desenvolveram DECH parece ser 
semelhante ao dos indivíduos sadios, a perda inicial de ácinos é, provavelmente, resultado 
do condicionamento quimioterápico.  
 
Palavras-Chave: Doença do enxerto contra o hospedeiro, imuno-histoquímica, glândulas 
salivares menores, fígado e transplante de células tronco hematopoiéticas.  
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ABSTRACT 
  
Chronic graft-versus-host disease (cGVHD) is an alloimmune inflammatory process, which 
results from a donor-origin cellular response (T cells) against host tissues. The organs 
mostly affected are skin, oral mucosa, salivary glands and liver. The aim of this study was 
to evaluate the histopathological findings of minor salivary glands (MSG) and liver of 
patients affected by cGVHD, comparing the findings each other and with those of the 
patients who did not develop cGVHD after HSCT and patients who were not underwent 
HSCT. MSG and liver samples from patients who underwent myeloablative HLA-matched 
HSCT from sibling donors, between 1994 and 2006, were analyzed. Fifty-seven patients 
were selected, being 36 with oral and hepatic cGVHD and 21 without GVHD. The 
diagnosis of cGVHD was defined through clinical/ laboratory criteria and follow-up. 
Samples from non-transplanted patients were also evaluated (19 MSG and 20 liver 
specimens). The specimens were stained with haematoxylin & eosin, periodic acid-Schiff 
(PAS), Masson's trichrome, reticulin and Perls, and immunolabeled for CD45, CD45RO, 
CD68, CD4, CD8, CD138, and AE1/AE3. The criteria defined in the classification 
proposed by the consensus meeting of the National Institutes of Health were used for the 
evaluation of all samples of both organs. Digital images of the PAS stained sections were 
used to estimate the MSG acinar area. In the liver of patients who developed GVHD it was 
observed a statistically significant increase in the number of CD45RO and CD8 
immunostained cells, comparatively with the other 2 groups. The results of the analysis of 
the NIH criteria in the liver showed that 12 of them showed significant correlation with the 
diagnosis of liver cGVHD and seven of them with elevated serum levels of at least one 
liver enzyme and / or bilirubin. The number of CD8+ and CD45+ cells/ mm
2
 in the MSG 
showed a predictive value for the diagnosis of liver GVHD. The relative number of CD45+, 
CD4+ and CD8+ cells in the MSG correlated with the same cell subpopulations in the liver. 
Concerning MSG samples, significant differences were found in the number of CD4, CD8, 
CD45 and CD45RO immunolabeled cells, when the two HSCT patients groups were 
compared. However, for CD68 and CD138, there were no differences. Finally, the  PAS+ 
 xi 
acinar area of MSG revealed significant differences among the three groups. The changes 
of MSG reflect those of the liver in patients with cGVHD and immunomarked subsets of 
cells were predictive of GVHD diagnosis in the liver. Considering the set of clinical and 
laboratory findings, MSG biopsies, that are easily obtained, might help to estimate hepatic 
changes in cGVHD patients. Since the relative number of lymphocytes in the MSG of 
HSCT patients who did not develop GVHD appears to be similar to those of healthy 
individuals, the initial loss of acini is probably a result of conditioning chemotherapy. 
 
Key words: Chronic graft-versus-host disease, immunohistochemistry, minor salivary 
glands, liver, hematopoietic stem cell transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
LISTA DE ABREVIATURAS  
 
 
ALL Acute lymphoblastic leukemia 
Allo-HSCT Allogeneic hematopoietic stem cell transplantation 
Alo-TCTH Transplante de células tronco hematopoéticas alogênico 
ALT Alanina transferase 
AML Acute myelogenous leukemia 
AP  Alkaline phosphatase  
APC Antigen presenting cells 
AST Aspartato transferase 
BAAF B cell activating factor 
BD/PTr Bile ducts/Portal tract ratio 
BMT Bone marrow transplantation 
BT Bilirrubina total 
BU Busulfan 
cGVHD Chronic graft-versus-host disease 
CML Chronic myelogenous leukemia 
CsA Cyclosporin A 
CY Cyclophosphamide 
DECH Doença do enxerto contra o hospedeiro 
DECHc Doença do enxerto contra o hospedeiro crônica 
FA Fosfatase alcalina 
GGT Gama glutamil transpeptidase 
GSM Glândula salivar menor 
 xiii 
GVHD Graft-versus-host disease 
HE Hematoxilina e eosina 
HLA Human Leukocyte Antigen 
HSCT Hematopoietic stem cell transplantation 
HSCT Hematopoietic stem cell transplantation 
Ig Immunoglobulin  
IgA Immunoglobulin A 
L-GVHD Liver graft-versus-host disease 
MALT Mucosa-associated lymphoid tissue 
MDS Myelodysplastic disorder syndrome 
mHA Minor histocompatibility antigens 
MHC Major histocompatilibity complex 
MSG Minor salivary glands 
MTX Methotrexate 
NC No correlation 
NIH National Institutes of Health  
PAS Periodic acid Schiff  
PCB Primary biliary cirrhosis 
PNH Paroxysmal nocturnal hemoglobinuria 
SAA Severe aplastic anemia 
SD  Standard deviation 
SPSS Statistical Package for the Social Sciences 
SPSS Statistical Package for the social sciences 
SS Síndrome de Sjögren 
 xiv 
TB Total bilirrubin 
TBI Total body irradiation 
TCTH Transplante de células tronco hematopoética 
Th1 Linfócitos T herper 1 
Th2 Linfócitos T helper 2 
Tregs Linfócitos T regulatórios 
VP VP-16 Etoposide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv 
 
 
 
 
SUMÁRIO 
 
 
 
INTRODUÇÃO 1 
CAPÍTULO 1: Salivary glands changes in hematopoietic stem cell transplantation: 
relationship with patients follow up   
 
8 
CAPÍTULO 2: Graft-vesus-Host disease in liver: a histological and 
immunohistochemical study 
 
27 
CAPÍTULO 3: Chronic GVHD after hematopoietic stem cell transplantation: 
histological and imunohistochemical correlation between liver and minor salivary 
glands changes 
 
 
48 
CONCLUSÃO 63 
REFERÊNCIAS 65 
ANEXO 71 
 
1 
 
INTRODUÇÃO 
O transplante de células tronco hematopoéticas (TCTH) é um recurso 
terapêutico utilizado para o tratamento de doenças hematológicas malignas além de outras 
doenças hematológicas não malignas e genéticas. Este tratamento apresenta a possibilidade 
de erradicação da doença hematológica maligna por meio do efeito enxerto contra leucemia 
ou enxerto contra tumor (Appelbaum, 2001). O número de transplantes alogênicos de 
células tronco hematopoéticas (alo-TCTH) vem crescendo, com mais de 25.000 alo-TCTH 
realizados anualmente em todo mundo (Ferrara et al., 2009). Este aumento se dá 
principalmente pelo desenvolvimento de novas estratégias, como o uso de sangue periférico 
do doador, os regimes de condicionamento não mieloablativos e o uso do cordão umbilical 
como fonte de células tronco, possibilitando a expansão das indicações do alo-TCTH, 
especialmente para aqueles pacientes mais idosos. (Welniak et al., 2007). A melhora na 
profilaxia antibiótica, nos tratamentos imunossupressores e na tipagem molecular dos 
doadores também tem contribuído com o aperfeiçoamento dos resultados dos transplantes 
(Ferrara et al., 2009).   
Apesar de todos esses avanços, a doença do enxerto contra o hospedeiro 
(DECH) continua sendo a maior complicação letal (não relacionada à recaída) do alo-
TCTH e está diretamente ligada à limitação de sua indicação (Welniak et al., 2007). Em 
virtude das novas tendências de transplantes que incluem os transplantes não aparentados, o 
número de pacientes que podem apresentar a doença do enxerto contra hospedeiro tende a 
aumentar significantemente (Ferrara et al., 2009). 
Na década de 60, Billingham (1966) formulou os três requisitos básicos para 
o desenvolvimento da DECH: (1) o enxerto deveria conter células imunocompetentes, 
posteriormente reconhecidas como sendo os linfócitos T maduros presentes no enxerto; (2) 
o receptor deveria expressar antígenos teciduais diferentes daqueles do doador, o que 
permitiria às células doadas reconhecer os tecidos do receptor como estranhos; e 
finalmente, (3) o receptor não deveria ser apto a desencadear uma reação imune capaz de 
eliminar as células transplantadas (Billingham, 1966). 
A DECH ocorre quando os linfócitos T do doador respondem a proteínas 
geneticamente definidas nas células do hospedeiro. As proteínas mais importantes são as do 
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Human Leukocyte Antigen (HLA), as quais são altamente polimórficas e codificadas pelo 
complexo principal de histocompatibilidade (MHC – major histocompatilibity complex). 
Proteínas HLA Classe I (A, B e C) são expressas em quase todas as células nucleadas do 
corpo em diferentes densidades.  Proteínas HLA Classe II (DR, DQ e DP) são expressas 
principalmente em células hematopoéticas (linfócitos B, células dendríticas e monócitos), 
mas também podem ter sua expressão induzida em várias outras células após um processo 
inflamatório ou lesão tecidual (Ferrara et al., 2009). 
Outras diferenças geneticamente determinadas entre o doador e o receptor de 
células tronco hematopoéticas, como aquelas situadas fora do loci HLA, como os antígenos 
de histocompatibilidade menores (mHA- minor histocompatibility antigens), podem 
influenciar a incidência da DECH aguda (Bleakley e Riddell, 2004; Goulmy et al., 1996). 
Os polimorfismos presente em ambos, doador e receptor, dos genes das 
citocinas relacionadas aos eventos inflamatórios da DECH, tais como o fator de necrose 
tumoral alfa, interleucina-10, interferon gama, estão implicados como fatores de risco para 
o desenvolvimento da DECH (Antim et al., 1992; Cavet et al., 1999; Lin et al., 2003; 
Dickinson et al., 2005). Estratégias futuras para encontrar o melhor doador possível 
provavelmente irão incorporar fatores genéticos relacionados e não relacionados ao HLA 
(Ferrara et al., 2009). 
A DECH aguda acomete principalmente a pele em aproximadamente 81% 
dos casos, o trato gastrointestinal em 54% e o fígado em 50% dos casos (Martin et al., 
1990). A pele é o local mais frequentemente afetado e geralmente o primeiro a ser 
acometido coincidindo com a “pega” do enxerto (Ferrara et al., 2009). A presença 
característica de rash cutâneo macropapular com prurido pode ser observada por toda a 
pele. Em casos mais graves, bolhas seguidas de ulceração podem ser vistas (Vogelsang et 
al., 2003).  
O envolvimento do trato gastrointestinal é caracterizado pela presença de 
diarreia que pode ser acompanhada de vômitos, anorexia e dor abdominal (Ferrara et al., 
1991). As alterações hepáticas causadas pela DECH podem ser difíceis de serem 
distinguidas de outras causas de disfunção hepática após o TCTH, tais como a doença 
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veno-oclusiva, toxicidade causada por drogas, infecções virais, sepsis ou sobrecarga de 
ferro (Ferrara et al., 2009).  
A gravidade da DECH aguda é determinada pela extensão do acometimento 
dos três órgãos alvos principais e pode ser graduada em quatro categorias: leve, moderada, 
grave e muito grave. O prognóstico é desfavorável, com cerca de 25% de sobrevida, para a 
forma grave e de 5% para a forma muito grave (Cahn et al., 2005). 
A doença do enxerto contra o hospedeiro crônica (DECHc) em contraste 
com a forma aguda, apresenta-se clinicamente com manifestações que lembram doenças 
autoimunes, como a síndrome de Sjögren, esclerodermia, lúpus eritematoso sistêmico e 
cirrose biliar primária (Shlomchik, 2007; Socie et al., 2010).  
Em pacientes com DECHc, a pele pode exibir eritema em máculas e placas, 
descamações, despigmentações, lesões liquenóides, atrofia e, em alguns casos, úlceras 
crônicas. Pode haver o desenvolvimento de doença colestática crônica no fígado e ainda o 
acometimento do trato gastrointestinal, o que pode resultar em perda de peso e má nutrição 
(Min, 2011). A DECHc comumente produz a síndrome sicca, a qual é causada pela 
destruição linfocítica de glândulas exócrinas, dentre elas o fígado e as glândulas salivares 
(Min, 2011).   
Diferentemente da DECH aguda, pouco se sabe sobre os mecanismos 
imunes que levam ao desenvolvimento da DECHc e da mesma forma, o grau de 
similaridade entre a DECHc e as diferentes doenças autoimunes. Embora a DECHc 
apresente manifestações de autoimunidade, ela somente ocorre em pacientes tratados com 
alo-TCTH (Socie et al., 2010).  
Ambas as formas da DECH, aguda e crônica, podem ser prevenidas pela 
depleção dos linfócitos T do enxerto. Isso leva a crer que a resposta imunológica dos 
linfócitos T do doador aos antígenos alogênicos do hospedeiro é essencial no 
desenvolvimento da DECH crônica, porém os mecanismos imunológicos específicos da sua 
patogenia não são totalmente estabelecidos (Socie et al., 2010). A quebra da tolerância 
imunológica à auto antígenos e alterações na função dos linfócitos T regulatórios 
CD4+CD25+FOXP3+ (Tregs) seriam os fatores promotores das manifestações autoimunes 
da DECHc (Sprent e Kishimoto, 2001; Soiffer, 2008).  
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A quebra da tolerância imunológica ocorre pela agressão ao timo causada 
pelo regime de condicionamento pré-transplante e/ou DECH aguda, levando a uma 
desregulação do mecanismo de tolerância central durante a reconstituição do sistema 
imunológico pós-transplante (Sprent e Kishimoto, 2001).  
Estudos em modelos murinos têm demonstrado que as Tregs são capazes de 
suprimir a DECH e que a deficiência destas células pode levar ao aumento da gravidade da 
doença (Socie et al., 2010). Outros estudos mostraram que pacientes com DECHc 
apresentaram menor quantidade de Tregs em comparação com aqueles sem DECHc (Zorn 
et al., 2005; Rieger et al., 2006).  
Além dos linfócitos T, evidências apontam que os linfócitos B também 
possuem um papel importante no desenvolvimento da DECHc, semelhantemente ao que 
ocorre nas doenças autoimunes (Socie et al., 2010). A participação dos linfócitos B na 
patogênese da DECHc foi revelada por estudos que observaram altos níveis séricos de fator 
ativador de células B (BAAF – B cell activating factor), uma citocina que regula a 
autoimunidade dos linfócitos B (Srantopoulos et al., 2007). Estudos têm demonstrado que 
os linfócitos B respondem aos mHA ligados ao cromossomo Y, o que explicaria a alta 
incidência, tanto da forma aguda quanto crônica da DECH, em homens que receberam 
enxerto de mulheres (Randolph et al., 2004; Miklos et al., 2005). Quando paciente e doador 
tem o HLA e sexo compatível supõe-se que os mHA codificados por genes autossômicos 
sejam os antígenos alvos (Socie et al., 2010). 
A cavidade oral representa um dos sítios de maior incidência da DECHc. Em 
um estudo retrospectivo realizado no Fred Hutchinson Cancer Research Center, em Seattle, 
EUA, foram revistos os prontuários médicos de 740 pacientes que desenvolveram DECHc 
após tratamento com TCTH mieloablativo. No momento do diagnóstico, a cavidade oral 
estava acometida em 333 (86%) dos pacientes, seguida pela pele acometida em 261 
pacientes (67%) e fígado, acometidos em 136 (35%) (Vigorito et al., 2009).  
Clinicamente, a DECHc oral apresenta-se como lesões liquenóides, 
eritematosas, atróficas e ulcerações. Estas alterações podem estar associadas à disfagia, 
alterações do paladar, restrição da abertura da boca e disfunção das glândulas salivares com 
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diminuição do fluxo salivar, além da presença de mucoceles (Villar et al., 2001; Filipovich 
et al., 2005; Pereira et al, 2007; Schubert e Correa, 2008; Boer et al, 2010).  
Microscopicamente, em mucosa oral, a DECHc apresenta atrofia do epitélio 
com a presença de corpos apoptóticos, degeneração hidrópica da camada basal, infiltrado 
inflamatório (de interface e em região sub-epitelial) e exocitose (Woo et al., 1997; Hiroki et 
al., 1994; Shulman et al., 2006, Horn et al., 1995). Ao exame histológico das glândulas 
salivares, observa-se infiltrado inflamatório linfo-plasmocitário peri-ductal e intralobular, 
com graus variáveis de atrofia acinar e fibrose (Shulman et al., 2006; Alborghetti et al., 
2005; Soares et al., 2005, Horn et al., 1995). Segundo Shulman et al. (2006) a DECHc 
ativa em glândula salivar está associada à presença de estroma periacinar e periductal com 
fibrose moderada ou intensa, enquanto que a presença de tecido fibroso denso com 
destruição acinar e ectasia ductal pode apenas representar agressão prévia. Alborghetti et al. 
(2005) mostraram as alterações do parênquima acinar das glândulas salivares menores 
(GSM) em pacientes com DECHc oral e que as mesmas foram  persistentes mesmo após 
tratamento imunossupressor. 
Em estudo imuno-histoquímico de GSMs acometidas pela DECHc, foi 
observado aumento de células CD45+, macrófagos (CD68+), e linfócitos T CD4+ e CD8+, 
com predomínio de células T citotóxicas (CD8+) em relação aos linfócitos T auxiliares 
(CD4+) (Soares et al., 2005). Este quadro é similar ao da Síndrome de Sjögren. Entretanto, 
nesta síndrome ocorre uma predominância de linfócitos T CD4+ sobre os CD8+ e o 
infiltrado peri-ductal é mais pronunciado que na DECHc (Harada et al., 1996). 
 Em mucosa labial de pacientes com DECHc, Soares et al (2005) 
demonstraram o aumento da presença de leucócitos CD45+, seguidos de linfócitos T 
CD8+, macrófagos (CD68+) e linfócitos T CD4+. A presença de linfócitos B (CD20+) foi 
rara nesse estudo. Outros estudos demonstraram a participação das células de Langerhans 
(CD1+) na forma liquenóide da DECHc em mucosa oral (Sato et al., 2006; Orti-Raduan et 
al., 2009). Estudo comparativo de líquen plano oral e DECHc demostrou a importância da 
liberação de perforina e granzima pelas células T citotóxicas (CD8+) na agressão à mucosa 
oral, com maior participação da perforina na indução de apoptose dos ceratinóticos na 
DECHc (Pimentel et al., 2010).  
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As alterações hepáticas podem ocorrer logo após o transplante. O 
diagnóstico diferencial em pacientes pós-TCTH incluem infecções virais, DECH, 
toxicidade por drogas, obstrução biliar, sobrecarga de ferro, hiperplasia regenerativa 
nodular, hiperplasia nodular focal e cirrose (McDonald, 2010; Kida e McDonald, 2012). 
As manifestações da DECH hepática em pacientes pós-TCTH tardios podem 
ocorrer de três formas: (1) Elevação assintomática dos níveis séricos de alanina transferase 
(ALT), fosfatase alcalina (FA), e gama glutamil transpeptidase como alterações 
laboratoriais isoladas e na ausência de icterícia, geralmente observada em pacientes com 
DECHc em algum outro órgão (Sullivan et al., 1981; Tomas et al., 2000). (2) Icterícia 
colestática de progressão lenta, que é hiperbilirrubinemia geralmente associada com FA 
sérica elevada, como resultado da agressão aos ductos biliares (Shulman et al., 1988). (3) 
Injúria hepatocelular aguda (DECH hepatítica), com elevação abrupta dos níveis séricos de 
ALT acima de 500U/L sem disfunção hepática prévia (Akpek et al., 2002). 
Microscopicamente, a DEHCc hepática é caracterizada por agressão aos 
ductos biliares e infiltrado linfocítico portal (Saxena, 2011). Os achados nos ductos biliares 
intra-hepáticos incluem alterações degenerativas, seguidas por necrose multifocal de células 
epiteliais isoladas, pleomorfismo nuclear, atrofia e, finalmente, desaparecimento dos ductos 
(McDonald, 2006).  
 Histologicamente não é possível distinguir a DECH aguda da crônica, já que 
seus achados histológicos são semelhantes (Shulman et al., 2006). Porém tem sido feita 
distinção entre dois padrões histológicos da DECH hepática, a forma clássica e a hepatítica 
(Ma et al., 2004), sendo que esta última tende a ocorrer no momento da diminuição da 
terapia imunossupressora ou após infusão de linfócitos (Kida e McDonald, 2012). A forma 
clássica da DECH hepática se caracteriza pela agressão ao epitélio dos ductos biliares, 
presença de infiltrado linfocítico portal e pela estrutura hepatocelular preservada e 
desprovida de inflamação lobular (Akpek et al., 2002). A forma hepatítica da DECHc é 
caracterizada pela presença de hepatite lobular, com agressão relativamente leve aos ductos 
biliares (Akpek et al., 2002).  
O acometimento hepático pela DECHc é comparado ao da cirrose biliar 
primária, e pode ser incluído na síndrome das glândulas secas (síndrome sicca), 
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caracterizada pela presença de olhos secos, boca seca e hiposecreção biliar e pancreática 
(Epstein et al., 1980). Na cirrose biliar primária, assim como na DECHc, há um 
comprometimento multi-sistêmico,  onde glândulas lacrimais e salivares estão acometidas 
em 70 a 100% dos pacientes (Epstein et al., 1980). 
As células dos ductos das glândulas salivares e dos ductos biliares são alvos 
preferenciais da DECH. Ambas são derivadas da endoderme e expressam alta densidade de 
HLA, necessários para o reconhecimento imunológico (Lauteuschlager et al., 1982; Nagler 
et al., 2004). A presença de linfócitos na espessura da parede dos ductos salivares e biliares 
danificados é evidência da linfocitotoxicidade contra antígenos de superfície destas células.   
A gravidade do envolvimento das glândulas salivares, tanto ao diagnóstico, como em 
biópsias sequenciais, poderia ter relação com o envolvimento hepático. Fatores agravantes 
prévios ou concomitantes também poderiam atuar.  
Considerando a alta incidência da DECHc oral e hepática e seu impacto nos 
resultados do tratamento pelo TCTH (Pavletic et al., 2005; Duarte et al., 2005) e, 
considerando ainda, a relação estrutural e histológica entre o fígado e as glândulas salivares 
(Epstein et al., 1980), a hipótese deste trabalho reside na possível correlação entre os 
achados histológicos da DECHc nas glândulas salivares com os do fígado e dos achados em 
ambos com alterações clínicas do paciente.  
Desta forma, o objetivo principal deste trabalho foi analisar os achados 
histológicos, sob técnicas convencionais e imunoistoquímicas, nas glândulas salivares 
menores e no fígado dos pacientes tratados com o transplante de células tronco 
hematopoéticas. Tendo como objetivos específicos: (1) Correlacionar os achados 
histológicos em glândulas salivares menores com os do fígado; (2) Investigar alterações 
histológicas na GSM que sinalizam o diagnóstico de DECHc hepática; (3) Comparar as 
subpopulações de células inflamatórias de ambos os órgãos e a área acinar produtora de 
muco das GSM em pacientes com DECHc, sem DECH e pacientes não tratados pelo TCTH 
e (4) Correlacionar as alterações histológicas em ambos os órgãos com alterações clínicas. 
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ABSTRACT  
The aim of this study was to discriminate the participation of damaging events preceding 
hematopoietic stem cell transplantation (HSCT) in minor salivary glands (MSG) of those 
affected by chronic graft-versus-host disease (cGVHD); to test the potential value of 
histological changes in predicting cGVHD severity and overall survival of patients. MSG 
of 57 HSCT patients, who developed or not oral cGVHD, were studied, comparatively with 
19 non-HSCT individuals. cGVHD changes were assessed according to the NIH consensus 
and Horn et al grading systems. Functional acinar area and mononuclear cells subset were 
set. The results showed significant increase for CD45, CD45RO, CD4, and CD8 
immunomarked cells/mm
2
 in cGVHD patients by comparing the 2 groups of HSCT 
patients. Increase in CD68
+
 cell counts were found in non-cGVHD compared with control 
group. Measurements of the PAS+ area were progressively lower in the 3 groups. The 
“Periductal lymphocytes with exocytosis into duct” feature correlated with worse overall 
survival and the “Periductal lymphocytic infiltrate” feature predicted the extensive form of 
cGVHD. Functional acinar loss begins with the conditioning chemotoxicity. Lymphocytes 
migrate through the ductal epithelium, leading to progressive acinar loss, which could 
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explain the persistence or worsening of xerostomia in patients who develop cGVHD and 
could possibly exert negative influence upon overall survival.  
Keywords: Graft-versus-host disease, pathology, immunohistochemistry, NIH system, 
morphometry. 
 
INTRODUCTION 
The oral cavity is frequently the primary source of hematopoietic stem cell 
transplantation (HSCT) morbidity [1]. Saliva plays a major role in maintaining oral health 
and function [2]. The loss of saliva leads to increased risk of dental caries, candidal 
superinfections, oral pain, mucosal friability and food sensitivity. Additionally, difficulties 
in speaking, chewing, and swallowing, as well as weight loss can also be observed [3,4]. 
Both, prior HSCT conditioning regimen and chronic graft-versus-host disease (GVHD) can 
cause salivary gland damage and inflammation, leading to xerostomia [5]. 
 Chronic GVHD (cGVHD) is the major late complication of HSCT, and is 
mediated by T lymphocytes targeting various organs and tissues, including the oral mucosa 
and salivary glands, leading to salivary hypofunction and oral damage [6]. 
The oral cavity may be the principal or sole site of involvement, in 50–83% of 
those affected by cGVHD [7]. On a clinical basis, mucosal lesions, salivary gland 
dysfunction, and taste disorders are similar to those of autoimmune disorders, such as 
lichen planus, lupus, and Sjögren syndrome [7-9]. The typical histological findings of 
cGVHD in salivary glands are periductal and diffuse glandular parenchyma lymphocyte 
infiltrate (CD8
+
 over CD4
+
), atrophy or destruction of acini, and fibrosis [5, 10-15]. 
Despite the advent of new therapies and management of cGVHD, minimal 
changes in this scenario have been observed, mainly due to an incomplete understanding of 
the pathogenesis of this disorder and there is a lack of an adequate classification system for 
diagnosis and patient follow up [1, 6]. 
Knowing the most important histological findings for diagnosis of minor 
salivary glands (MSG) cGVHD and understanding the mononuclear subsets participation in 
salivary glands after HSCT can contribute to a better management of those patients.  
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The goal of this study was to assess the residual acinar area and lobular 
mononuclear cell subsets in order to improve the understanding of the relative participation 
of the conditioning regimen for transplantation and development of cGVHD after HSCT; to 
test the potential value of histological changes in predicting cGVHD severity and overall 
survival of patients. 
 
PATIENTS AND METHODS  
 
This was a retrospective analysis of patients who underwent ablative HLA- 
matched HSCT from sibling donors. After a search of the data basis of the Bone Marrow 
Transplantation Unity of the University of Campinas Clinical Hospital, 57 patients who 
fulfilled the inclusion criteria were selected.  Inclusion criteria included complete medical 
history and lip biopsy with MSG represented. Exclusion criteria included incomplete 
follow-up data, and unavailable or insufficient paraffin material for new cuts. Thirty six 
patients with chronic oral GVHD composed the first group, and 21 patients who never 
developed GVHD composed the second group. Control group consisted of 19 MSG from 
free surgical margins of biopsies of non-inflammatory lesions in the lip. The biopsy 
specimens were obtained on the day in which the disease was clinically diagnosed or on the 
protocol day +100 post-HSCT. Samples were collected from the lower inner lip, about 10 
mm beneath the vermilion border through a 4 mm-punch, under local anesthesia. Patients’ 
clinical data are summarized in table 1. 
Paraffin embedded tissue were serially sectioned at 4 µm thickness and stained 
with H&E and periodic acid Schiff (PAS). All specimens were assessed for histological 
cGVHD features according to: 1- the National Institutes of Health (NIH) consensus 
pathology working group (Table 2) [15] and 2- Horn et al [17] grading systems (Table 2). 
Immunohistochemical study was performed through the standard polymeric method. 
Briefly, the histological sections were deparaffinized in xylene, and rehydrated. The 
primary monoclonal antibodies used were: CD4 (clone OPD4 at a dilution 1:100); CD8 
(clone C8/144B,  at a dilution 1:200); CD45 (clone 2B11+PD7/26, at a dilution 1:500); 
CD45RO (clone UHCL-1, at a dilution 1:700); CD68 (clone KP1, at a dilution 1:700); 
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CD138 (clone MI15,  at a dilution 1:200), all distributed by DAKO (Dako Cytomation, 
Carpinteria, CA, USA).  A steamer was used for epitope retrieval and the EnVision 
polymer (DAKO) as the reaction amplifier. Appropriate positive and negative controls were 
included in each essay. Staining was achieved with 3,3-diaminobenzidine 
tetrahydrochloride (Sigma, St Louis, Missouri, USA) and counterstaining with Mayer’s 
haematoxylin. Unsatisfactory sections were excluded and the procedures were repeated.  
Quantitative analysis was performed in 400x digital images in 10 blindly and 
randomly fields, either, for PAS- and immuno- stained sections of each patient. The number 
of ducts with lymphocytes in exocytosis into epithelium per mm
2
 was also recorded, 
through an Olympus CH30 optical microscope (Olympus Center Valley, PA, USA), in high 
(x400) magnification, in the CD45 stained sections. 
For the morphometric study, PAS stained digital images were analyzed using two 
softwares.  With the LimiarK software, the digital images were segmented according to the 
color spectrum; using the Quant6 software, the targeted area was calculated, providing the 
value of PAS positive area/ total area ratio. Both LimiarK and Quant6 software were 
developed by Randall Luis Adam, volunteer researcher of the Institute of Computing, 
UNICAMP, São Paulo, Brazil. Digital images from immune-marked samples were 
analyzed using Imagelab 2000
®
 (Image analysis system, 2000, Diracom, Sao Paulo, Brazil). 
The mean of PAS
+
 relative area and the mean of immunomarked cells/mm
2
 in each MSG 
sample were used for statistical analysis.  
Statistical Package for the Social Sciences (SPSS) for Windows 14.0 was used to 
perform statistical analysis. The following tests were applied: Spearman’s or Pearson’s 
correlation, Anova and the Kaplan-Meier method (ref. 18). To analyze and compare 
actuarial curves of overall survive the log-rank test was used (ref. 19). The forward 
stepwise Wald test, in conjunction with the Cox regression analysis (ref. 20), was also used 
to assess the multivariate predictors of outcome to overall survival. P values <0.05, were 
considered statistically significant.  
This study was approved by the Research Ethics Committee of the Faculty of 
Medical Sciences, University of Campinas (process 598/2002). 
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RESULTS  
The NIH feature “acinar degeneration/interstitial fibrosis/ductal ectasia” (Figure 
1) showed significant differences among patients who had or not extensive cGVHD 
(p=0.03) and, also, significant differences comparing patients who developed or not 
cGVHD (p=0.03). However, Horn’s feature “ductal dilation”, as an isolated criterium, did 
not correlate with the cGVHD clinical form, using Pearson’s correlation. Moreover, no 
significant difference in the degree of ductal dilation was found comparing patients who 
developed or not cGVHD. 
Horn’s “periductal lymphocytic infiltrate” finding best predicted the clinical 
extensive form of cGVHD (p=0.04).  
Using the Kaplan-Meyer method and Log-Rank test, the feature presenting the 
highest worse influence on overall survival (p=0.007) was demonstrated to be the NIH 
finding of “periductal lymphocytes with exocytosis into duct” (Figure 2). The univariate 
Cox analysis confirmed this result, the relative risk for dead was 5.74 (p=0.01; CI 95%: 
1.33–24.6).   
The objective counting of the relative number of ducts with lymphocytes 
exocytosis displayed a significant correlation with the subjective evaluation of the presence 
(or absence) of the NIH feature “periductal lymphocytes only with exocytosis into duct” 
feature (p=0.004). However no correlation with cGVHD diagnosis or extensive/localized 
form of the disease was found.  
 The results showed that the relative number of positive cells for CD45, 
CD45RO, CD4 and CD8 were incresed in cGVHD patients by comparing the 2 groups of 
HSCT patients (Figure 3). No differences however, were found between the control group 
and non- cGVHD patients for the same markers. For CD68, we found no differences 
between the 2 groups of HSCT patients, but there were significant differences between 
control group individuals and non- cGVHD patients values. Positive cells for CD68 were 
increased in cGVHD and non-GVHD patients by comparing with control group (Figure 3).  
PAS
+
 relative acinar area exhibited significant differences when the 3 groups 
were compared wih each other (Figure 4). We found decreased PAS+ acinar area in 
cGVHD group regarding HSCT patients (p<0.001). Also, was showed decreased PAS+ 
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acinar area in non-cGVHD patients by comparing with control group (p=0.006). These 
results are summarized in table 3. After applying several tests, no significant differences 
were found in the number of ducts with exocytosis, comparing patients with localized or 
extensive cGVHD. Likewise, no differences were found for CD138
+
 cells comparing the 3 
groups of individuals (Figure 3). 
 
DISCUSSION 
The histopathological examination of MSG can aid to set cGVHD diagnosis, 
especially by ruling out drug toxicity and infections with atypical clinical features [21]. 
Correa et al [22] found an association between the involvement of MSG and oral mucosa in 
cGVHD after HSCT and decrease in patient survival. The histological features that have 
been reported to be associated with cGVHD on MSG are lobular and periductal 
lymphocytic infiltrate, acinar atrophy / destruction, and fibrosis [10-12]. Horn et al [17] in 
1995, proposed a system for mucosal and salivary glands cGVHD diagnosis and grading. 
After comprehensive discussions among HSCT experts, the National Institutes of Health 
(NIH) consensus criteria for clinical trials in chronic graft-versus-host disease (GVHD) 
defined the most important diagnostic criteria for chronic GVHD. The recommendations of 
the NIH histopathology working group were published by Shulman et al [15] in 2006. With 
the aim of testing the value of these features in predicting cGVHD severity and overall 
survival of patients, we assessed all the criteria in found in the publications by Horn and 
Shulman (table 2), on the MSG specimens of the 3 groups of individuals. The NIH 
“periductal lymphocytes only with exocytosis into duct” feature was found to be important 
to predict cGVHD overall survival of patients. Lymphocytes exocytosis reflects high 
inflammatory activity and, consequently, progressive acinar loss.  Xerostomia can be a 
distressing symptom, and decreased salivary flow may lead to reduced food intake, dental 
caries, and oral mucosal infection [23]. Oral dryness is associated with lower health-related 
quality of life [24] and can be an additional factor in the reduction of the overall survival of 
these patients. Although these results should be regarded with caution due to the small 
number of patients in our cohort, they stress the importance of improving the management 
of oral cGVHD inflammation in long-term survivors of allogeneic HSCT. It is necessary to 
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validate these results studying larger series of patients from different institutions. 
Significant correlation was also found between the objective counting of ducts with 
exocytosis and the subjective assessment (present or absent) of the "periductal lymphocytes 
only with exocytosis into duct". Therefore, the subjective evaluation can be considered 
reliable. However, the relative number of ducts with exocytosis displayed no prognostic 
relevance. We believe that these results can be explained by the staining used for 
evaluation. The subjective feature was assessed on H&E samples and only cases with 
significant lymphocyte exocytosis could be discerned. The counting of ducts with 
exocytosis was performed on CD45 immunolabeled specimens that allow easy 
identification of inflammatory cells permeating ductal epithelium, even when sparse. 
Therefore, the prognostic value of periductal lymphocytes permeating the epithelium 
depends on inflammatory severity. 
Regarding systemic cGVHD involvement, Horn’s “periductal lymphocytic 
infiltrate” feature was found to best predict the clinical extensive form of cGVHD. Oral 
cGVHD often coexists with cutaneous, hepatic or ocular cGVHD [25]. Our results are in 
keeping with those of Nakamura et al [10] whose results revealed the histological 
alterations in MSG better reflected the cGVHD status [10]. 
Ductal dilation has been described as one of the histological findings for 
cGVHD diagnosis [10-12, 17]. However, it could only be the consequence of acinar 
atrophy and fibrosis, due to the conditioning regimen. In fact, no significant differences 
were found in the degree of ductal dilation, comparing patients who developed or not 
cGVHD. On the other hand, when ductal dilation, fibrosis and acinar degeneration were 
assessed together, as recommended by Shulman et al [15], significant differences were 
found between cGVHD and non-cGVHD patient samples. This reiterates that tissue 
destruction caused by T cells is more important than the simple presence of ductal dilation. 
Concerning immunohistochemical analysis, we found a significant increase of 
CD45
+
, CD45RO
+
, CD4
+
 and CD8
+
 cells in MSG of cGVHD patients, with a predominance 
of CD8 over CD4 phenotype, comparatively with the other 2 groups. These results reiterate 
the T cells role on pathogenesis of cGVHD. However, no differences were found between 
control group (non-HSCT patients) and non- cGVHD patients for the same markers. 
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Therefore, we can infer that the massive lymphocyte infiltrate was part of the GVHD 
process and not of the chemo-radioterapy regimen preceding HSCT. Our results also 
revealed the lymphocyte infiltrate related to cGVHD is not the only mechanism for salivary 
cells loss. PAS
+
 acinar area exhibited significant differences when the 3 groups were 
compared to each other. A progressive loss of functional acini, probably begins for the 
cytotoxicity of antineoplastic and pre-transplant conditioning drugs and progress with 
cGVHD process. In fact, conditioning regimens have been shown to promote oral toxicity 
and also injure salivary glands [26], which justifies xerostomia in patients post-HSCT even 
when these do not develop cGVHD.  The PAS relative area in non-HSCT patients 
corresponded to 36% of glandular parenchyma, in HSCT patients who did not develop 
cGVHD corresponded to 25%, and in cGVHD patients, to 3% of glandular parenchyma.  
Severe involvement of MSG in cGVHD results in the total destruction of 
secretory units and thus permanent and profound oral dryness [27]. Imanguli et al (2010) 
[28] findings revealed the usefulness of MSG biopsy in identifying the patients most likely 
to benefit from cGVHD treatment. Patients in the late process of the disease, manifested by 
extensive destruction of MSG tissues with fibrosis and atrophy, would probably be unlikely 
to regain significant function. Our results, corraborate those of Imanguli et al (2010) [28]: a 
pathological examination of the MSGs is useful for diagnosis, grading of  cGVHD and 
screening patients for treatment.  
Unlike our results, Soares et al (2005) [14] found increased CD68
+
 cells 
number in cGVHD patients, compared with non- cGVHD HSCT patients. This discrepancy 
might be explained by the development of previous acute GVHD. In our cGVHD cohort 
only 4 patients had developed previous acute GVHD. In the third phase of acute GVHD, 
allogeneic activated T-cells travel to target tissues and inflammation and tissue destruction 
occurs [29, 30]. Donor CD4
+
 T cells can interact with donor macrophages, which present 
recipient antigens. Tissue macrophages can also induce donor CD4
+
 T cells to produce 
inflammatory mediators and activate macrophages [31]. 
Significant differences were found in relative CD68+ cell numbers, comparing 
control group and non- cGVHD patients. The mucosa-associated lymphoid tissue (MALT) 
is the diffusion system of small concentrations of lymphoid tissue found in various sites of 
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the body, such as the gastrointestinal tract, salivary glands, eyes, and skin. MALT is 
populated by lymphocytes such as T cells and B cells, as well as plasma cells and 
macrophages. Normal lymphoid tissue is destroyed in pre-transplant conditioning, 
following the HSCT, immune reconstitution takes place, and successful reconstruction of 
the T-cell compartment is known to require one to two years [32]. However, monocytes and 
natural killer cells reach the normal range by day 30 [33]. All our HSCT non-GVHD 
biopsies were collected around day 100 post-HSCT, when the T cells had not yet fully 
recovered, and therefore, were not in a greater number. However, the macrophages had 
already been reconstituted and the cytokines released during the pre-transplant conditioning 
recruit these cells.  
Several recent studies have pointed out the participation of B cells on cGVHD 
pathogenesis [34-37]. The role of B cells in cGVHD was enhanced by patient response to B 
cell depletion cGVHD therapy based on rituximab [38]. Autoantibody formation in patients 
with cGVHD has been observed, however their role in cGVHD pathogenesis has not yet 
been elucidated [39]. At least, the role of B cell activity in cGVHD is underscored by the 
observation of high plasma levels of B cell activating factor, a cytokine that appears to 
drive B cell auto-immunity, in patients with cGVHD [37]. Perhaps B cells might be acting 
as antigen presenting cells, providing constant stimulation to infiltrating T cells, leading to 
tissue damage [40]. Infiltration of tissue by B cells (CD20
+
) are reported to be virtually 
absent in oral cGVHD [10, 14], this however, is not the case of plasma cells. In our cohort, 
plasma cells (CD138
+ 
cells) contributed with a significant part of the infiltrate, despite 
having found no differences in CD138
+
 cells relative numbers, when the 3 groups were 
compared. The MSGs of the control group of our cohort were obtained from specimens of 
surgically removed benign conditions such as lentiginous macules, nevi and cysts. It is 
possible that although not in direct contact, the proximity with these benign lesions may 
have resulted in the increase in the number of immunocytes in these glands. With respect to 
the subpopulation of these cells, immunoglobulin A (IgA)-secreting plasma cells are known 
to be located adjacent to the duct and acini of salivary glands and predominate in the major 
and minor salivary glands over plasma cells producing other Immunoglobulin (Ig) isotypes 
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[41]. Further studies are necessary to investigate the densities and Ig class proportions of 
plasma cells in HSCT glands. 
In summary, ours findings show that functional acinar loss begins with the 
conditioning chemotoxicity and may be the cause of long standing xerostomia that is 
observed after HSCT, even in patients not developing cGVHD. Lymphocytes migration 
through ductal epithelium, leading to progressive acinar loss, could explain the persistence 
or worsening of xerostomia in patients who develop cGVHD and might exert negative 
influence in overall survival. 
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TABLES: 
 
Table 1. Patients’ clinical data 
 
Variable n = 57  
Age, median (range)* 28 (12-59) 
Gender, n (%)  
    Male  29 (51) 
    Female  28 (49) 
GVHD  
    Absent 21 (37) 
    Present 36 (63) 
Disease, n (%)   
    ALL 7 (12) 
    CML 31 (54) 
    MDS 4 (7) 
    AML 5 (9) 
    SAA 7 (12) 
    PNH 1 (2) 
Conditioning regimen  
    BU + CY 45 (78) 
    BU + VP-16 + CY 4 (7) 
    CY + TBI 5 (9) 
    CY 2 (4) 
    CY + Melphalan 1 (2) 
GVHD prophylaxis  
    CsA/MTX 51 (89) 
    CsA/Corticosteroid 6 (11) 
Mean Follow-up, median (range) * 122 (8-180) 
    Living 36 (63) 
Cause of death, n (%)  
    Chronic GVHD  6 (11) 
    Other causes 15 (26) 
ALL: acute lymphoblastic leukemia; CML: chronic myelogenous leukemia; MDS: myelodysplastic disorder 
syndrome; AML: acute myelogenous leukemia; SAA: severe aplastic anemia, PNH: paroxysmal nocturnal 
hemoglobinuria. 
*Age in years. 
** Follow-up in months. 
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Table 2. Histological cGVHD features in salivary glands according to Horn et al (1995) 
and NIH consensus systems (Shulman et al., 2006). 
Histological feature Grading 
Interstitial inflammation* 
Absent 
Mild 
Marked 
Acinar destruction* 
Absent  
Diffuse  
Complete 
Ductal dilation* 
Absent  
Mild 
Marked 
Squamous metaplasia* 
Absent 
Present 
Mucous pooling* 
Absent 
Present 
Interstitial fibrosis* 
Absent 
Mild 
Marked 
Duct cell proliferation* 
Absent 
Present 
Periductal lymphocytic infiltrate* 
Absent 
Present 
Destruction of ducts* 
Absent 
Mild  
Marked 
Periductal lymphocytes ONLY with exocytosis into duct** 
Absent 
Present 
Lymphocytes (only) around & migrating into acinar units** 
Absent 
Present 
Periductal fibrosis** 
Absent 
Present 
Oncocytic metaplasia (in children)** 
Absent 
Present 
Periductal mixed chronic infiltrate** 
Absent 
Present 
Apoptotic cells in ducts/acini** 
Absent 
Present 
Acinar degeneration/interstitial fibrosis/ductal ectasia** 
Absent 
Present 
Loss of polarity of ductal  epithelial cells** 
Absent 
Present 
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Table 3. Comparative analysis of the immunostained inflammatory cells subsets relative 
numbers and PAS+ relative acinar area in minor salivary glands of HSCT patients and 
healthy individuals  
 
With GVHD Without GVHD  Control group    
N Mean SD N Mean SD N Mean SD P
ǂ
 P
£
 P
€
 
CD45* 35 667.60 772.12 21 211.24 94.04 19 202.83 166.70 0.001 0.013 0.84 
CD45RO* 6 527.44 353.07 9 111.45 73.62 17 85.63 60.64 0.03 <0.0001 0.38 
CD4* 27 203.28 294.15 22 43.33 47.51 19 58.85 41.93 0.01 0.040 0.27 
CD8* 31 488.05 436.19 21 130.58 79.21 19 193.70 203.14 <0.0001 0.008 0.21 
CD68* 33 259.33 242,70 22 164.64 145.16 19 88.40 68.78 0.07 0.004 0.036 
CD138* 25 307.36 271.62 21 239.98 169.30 19 213.94 249.80 0.3 0.24 0.71 
PAS
#
 34 0.032 0.007 22 0.2532 0.0890 19 0.359 0.033 <0.0001 <0.0001 0.006 
*cells/mm
2
, 
#
relative area (PAS+area/ total MSG area) 
ǂ
with GVHD versus without GVHD, 
£
with 
GVHD versus control group, 
€
Without GVHD versus control group 
 
FIGURES  
 
Figure 1. Minor salivary gland sample in oral chronic GVHD. The NIH feature “acinar 
degeneration/interstitial fibrosis/ductal ectasia” (H&E, original magnification X100). 
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Figure 2. Global survival related to the presence (or not) of the “periductal lymphocytes only with 
exocytosis into duct” NIH consensus feature. 
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Figure 3. Immunostained minor salivary glands sections targeting for CD4, CD8, CD45, CD45RO, 
CD68 and CD138 in control group-, non- GVHD and cGVHD patients. Original magnification 
x400. 
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Figure 4. Digital images taken for LimiarK software analysis. A. MSG of the control group, A1. 
Segmented image of MSG of the control group; B. MSG of HSCT patient without oral cGVHD, 
B1. Segmented image of MSG of HSCT patient without oral cGVHD; C. MSG of an oral cGVHD 
patient, C1. Segmented image of MSG of an oral cGVHD patient. (PAS; original magnification 
X400). 
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ABSTRACT 
Background and Aim: Chronic graft versus host disease (cGVHD) after hematopoietic 
stem cell transplantation (HSCT) is a multisystem alloimmune and autoimmune disorder. 
cGVHD occurs when donor T cells react to the histo-incompatible antigens of the recipient. 
The organs mostly affected are skin, oral mucosa, salivary glands, and liver. The purpose of 
this study was to analyze histological features for diagnosis of liver GVHD, the 
contribution of T cell subsets in liver GVHD and the correlation between the NIH 
Consensus Criteria for liver cGVHD and laboratory changes. 
Methods: This restrospective study included liver biopsy samples of 36 cGVHD patients 
who underwent allogeneic HSCT after myeloablative conditioning and subsequently 
required systemic treatment for cGVHD and concomitant infection or medication toxicity 
had been ruled out. Biopsy sections were stained for H&E and for immunohistochemical 
technique targeting CD45, CD4, CD8, CD68, CD45RO and CD138. The samples were 
analyzed based on NIH criteria for liver cGVHD. Digital images were analyzed through 
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Imagelab® software for subsets T cells quantification. Liver biopsies from 20 healthy non-
HSCT subjects were analyzed and considered as the control group.  
Results: An increased number of CD8 and CD45RO immunomarked cells were observed 
in cGVHD liver tissue, compared with the liver biopsies from the control group. A positive 
correlation was found between immunomarked cells/mm
2
 in portal areas and the NIH 
cGVHD criteria for “final” diagnosis of cGVHD. Nevertheless, twelve histological features 
found in liver and increase of the serum levels of aspartate transferase, alanine transferase 
and alkaline phosphatase showed positive correlation with liver cGVHD NIH diagnosis.  
Conclusion: The results suggested that T cells (CD8+ and CD45RO+) play an important 
role in the pathogenesis of liver GVHD. Five NIH cGVHD Consensus Criteria were found 
to correlate with liver cGVHD diagnosis. Significant correlation was found between 
changes in the liver enzyme levels and GVHD diagnosis. Our findings support the liver 
NIH cGVHD Consensus Criteria for histological liver cGVHD for the improvement of 
GVHD diagnosis. 
 
INTRODUCTION 
Chronic graft versus host disease (cGVHD) remains a major cause of late 
morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-
HSCT) (Martin et al., 1990; Lee et al., 2002). The incidence of cGVHD following allo-
HSCT ranges from 25% to 80%, the occurrence  of cGVHD is associated with immune 
dysfunction and thus, a risk of infection and reduced quality of life (Baird and Pavletic, 
2006), despite the fact that cGVHD is also associated with lower relapse rate by the graft 
versus-leukemia effects (Lee et al., 2002). The syndrome has features resembling 
autoimmune disorders and affects a wide spectrum of organs, resulting in systemic 
manifestations that can involve skin, oral cavity, liver along with other sites (Lee et al., 
2002; Vigorito et al., 2009). 
Liver dysfunction is a frequent complication of hematopoietic stem cell 
transplantation (HSCT), occurring in 50–72% of patients with mortality rates ranging 
between 4 and 15% (Ho et al., 2004; Strasser, 1999; El Sayed et al., 2004; Tomas et al., 
2000). Among earlier post-HSCT hepatobiliary complications are sinusoidal obstruction 
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syndrome, cholestatic disorders (cholangitis lenta, acute graft-versus-host disease, and 
drug-induced liver injury, fungal and bacterial infections, and acute hepatocellular injury. 
Latterly, hepatobiliary complications are cGVHD, chronic hepatitis C or B, cirrhosis and 
iron overload (McDonald, 2010). 
Liver cGVHD (LcGVHD) is characterized by the destruction of bile duct 
epithelium followed by progressive cholestasis, with elevations in serum alkaline 
phosphatase (AP), γ-glutamyl transpeptidase and serum bilirubin levels. It resembles 
primary biliary cirrhosis (PBC) clinically and histologically (Strasser et al., 2000). The 
diagnosis of liver cGVHD is based on the presence of clinical jaundice and changes in liver 
enzymes, but sometimes, liver biopsy can be useful as a complimentary diagnosis when 
other complications related with the HSCT should be ruled out (Strasser et al., 2000). 
The goal of this study was to analyze the most relevant histopathological 
features for LcGVHD diagnosis, to correlate the NIH final diagnosis for LcGVHD with 
laboratorial changes and, to identify the leucocytes subsets in the liver cGVHD. 
 
PATIENTS AND METHODS 
This was a retrospective analysis which enrolled the 36 patients who survived 
100 days or more after allo-HCT between 1994 and 2006. These patients underwent an 
allogeneic HLA- matched HSCT after myeloablative conditioning, who had submitted to a 
liver biopsy due to the clinical suspicion of LcGVHD. Clinical and epidemiological data 
were obtained from the medical chart. 
The hepatic involvement of cGVHD was diagnosed by simultaneous clinical 
and laboratory parameters and by liver biopsy according to Shulman et al., 2006. Viral 
hepatitis was excluded by standard serological tests for hepatitis A, B, C. Herpes simplex 
infection as well as varicella zoster were excluded by absence of cytopathologic features of 
viral inclusions. Each patient’s recent medication history was reviewed to assess potential 
hepatotoxic drug reactions. The patients’ clinical data are summarized in table 1. 
Histological study 
Liver biopsy was performed by the percutaneous needle biopsy. The tissue 
specimens submitted to subsequent histologic analysis were fixed in 10% buffered formalin 
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and paraffin-embedding. Tissue blocks were serially sectioned with 4 µm of the thickness. 
The histologic sections were stained with hematoxylin-eosin, Masson’s trichrome, reticulin 
and Perl’s stain (special histochemical were performed with standard methodologies). All 
histological specimens were subsequently reviewed by one expert hepatic-pathologist by 
conventional light microscopy. The histologic features were assessed semiquantitatively 
according to two previously described coding systems (Quaglia et al., 2007; Shulman et al., 
2006), with some modifications (Table 2). The histopathologic diagnosis for LCGVHD was 
carried out as proposed by National Institutes of Health (NIH) consensus pathology 
working group criteria on cGVHD (Shulman et al., 2006). The Final diagnosis of NIH 
consensus integrates the histopathologic results and the clinical context, and is summarized 
in 1 to 4 categories: no GVHD, possible GVHD, consistent with GVHD and definitive 
(unequivocal) GVHD. 
Immunohistochemical study 
The bile ducts/ductular reaction were evaluated with AE1/AE3 immunostains. 
Mononuclear subsets were evaluated with CD4, CD8, CD45, CD45RO, CD68 and CD138. 
Histological sections (4 µm thick) were obtained from the paraffin-embedded tissue 
specimens, then deparaffinized in xylene, and rehydrated. The immunohistochemistry was 
performed using the standard polymeric method. The primary antibodies used were 
monoclonal mouse anti-human from DakoCytomation/DAKO, directed to: 1- cytokeratin, 
clone AE1/AE3, dilution 1:100; 2- T-helper cells (CD4+), clone OPD4, dilution 1:100; 3- 
cytotoxic T cells (CD8+), clone C8/144B, dilution 1:200; 4- Leucocyte Common Antigen 
(CD45), clone 2B11+PD7/26, dilution 1:150; 5- CD45RO, clone UHCL-1, dilution 1:100; 
6- Macrophages (CD68), clone KP1, dilution 1:700; 7- Plasma cell (CD138), clone MI15, 
dilution 1:200. All antibodies were from DAKO (Dako Cytomation, Carpinteria, CA, 
USA). A steamer was used for epitope retrieval and the EnVision polymer (DAKO) as the 
reaction amplifier. Reactions were performed using appropriate positive and negative 
controls. Staining was achieved with 3,3-diaminobenzidine tetrahydrochloride (Sigma, St 
Louis, Missouri, USA) and counterstaining with Mayer’s haematoxylin. Unsatisfactory 
sections were excluded and the procedures were repeated. 
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For quantitative analysis, digital images were obtained through a Power Shot 
A630 Canon camera connected to a Nikon Eclipse E200 microscope, under a 40x objective. 
The number of captured microscopic fields ranged with the size and amount of portal tracts 
by liver samples. Thus, enough fields were photographed in order to sufficiently analyze all 
or ideally, ten complete portal tracts. Digital images were analyzed through Imagelab® 
software (Image analysis system, Diracom, São Paulo, Brazil) for cell quantification and 
portal tracts measurements. The mean number of immunomarked cells/mm
2
 by portal tract 
was used for statistical analysis. Additionally, a control group for evaluation of 
mononuclear subsets, liver biopsies from 20 healthy non-HSCT subjects, whose were 
potentials donors for liver transplantation, was analyzed. 
Statistical Analysis 
To perform statistical analysis, Statistical Package for the Social Sciences 
(SPSS) for Windows 14.0, was used and P values <0.05, were considered statistically 
significant. The tests applied were, the Spearman or Pearson correlation, Student t-test and 
Kaplan-Meier method (Kaplan and Maier, 1958), which analyzed and compared actuarial 
curves of overall survive using the log-rank test (Mantel and Haenze, 1958). 
 
RESULTS 
The number of complete portal tracts ranged from 1 to 15 (median 4). Twenty-
three biopsies had from 1 to 5 portal tracts, 8 biopsies had 6-10 portal tracts and 5 samples 
had more than 10 portal tracts. The biopsy day post-HSCT ranged from 77 to 2380 (median 
257) with 2 biopsies taken before 100 days post-HSCT. 
Seven histological features showed correlation with at least one liver serum test 
(aminotransferases or bilirubin). Decreased bile duct/portal tract ratio (BD/PTr) was 
correlated with Total bilirubin (TB) (r=33%, p=0.04), alanine transaminase (ALT)  (r=37%, 
p=0.02) and aspartate transaminase (AST) (r=41%, p=0.01); lobular inflammation and  
lobular inflammation type (lymphomononuclear or polymorphonuclear) were correlated 
with AST (r=35%, p=0.03; r=45%, p=0.006 respectively) and AP (r=52%, p=0.001; 
r=42%, p=0.01 respectively); bile ducts infiltrated by lymphocytes was correlated with 
ALT (r=53%, p=0.001) and AST (r=46%, p=0.004); focal necrosis in parenchyma, bile 
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duct epithelium degenerative changes and  periportal interface hepatitis were correlated 
only with AP (r=44%, p=0.007; r=36%, p=0.03 and r=35%, p=0.03 respectively) (Table 3).  
In addition to these histological findings, other 5 histological features showed 
correlation with NIH consensus final diagnosis for LcGVHD. Bile duct epithelium 
degenerative changes, portal inflammation, lobular inflammation and focal necrosis in 
parenchyma showed a stronger correlation with NIH consensus final diagnosis (r=66%, 
p<0.0001; r=54%, p=0.001, r=51%, p=0.001 and r=51%, p=0.001 respectively). 
Furthermore, NIH final diagnosis were correlated with lobular inflammation type (r=46%, 
p=0.004), bile ducts infiltrated by lymphocytes (r=43%, p=0.01), confluent necrosis 
(r=42%, p=0.01), decreased bile duct/portal tract ratio (r=40%; p=0.01), periportal interface 
hepatitis (r=39%, p=0.01), central perivenulitis (r=36%, p=0.03), eosinophilic portal 
inflammation (r=36%, p=0.03) and endothelitis (r=33%, p=0.04) (Table 3).  
The histological findings of bile duct epithelium degenerative changes were 
positive in 83% of all cases, most of them showing focal involvement. Results were 
correlated with bile ducts infiltrated by lymphocytes (r= 74%, p<0,001), decrease bile 
ducts/portal tracts ratio (r=43%, p = 0.009) and lobular inflammation (r = 34%, p = 0.03). 
Portal inflammation, the most frequent histologic feature (94%), showed mild or moderate 
involvement in most of cases. In addition to the features previously described, the 
following histologic features were observed in more than 60% of the samples: Lobular 
inflammation (83%), Reticulo-endothelial iron (83%), focal necrosis in parenchyma (75%), 
liver cell ballooning (69%), fibrosis (67%), bile ducts infiltrated by lymphocytes (64%) and 
hepatocellular iron (64%). The interface hepatitis was present in exactly 50% of the cases. 
HOwever, chronic cholestasis and arteritis were observed in only one sample (3%), 
whereas periductal lymphoid aggregates were not observed.  
The following histologic features were the less frequent in the assessed 
samples: apoptosis (39%), confluent necrosis (33%), endothelitis (31%), central 
perivenulitis (28%), periductal fibrosis (14%), decrease BD/PTr (14%), intrahepatocytic 
cholestasis (14%), eosinophilic portal inflammation (14%), ductular reaction (11%), 
canalicular cholestasis (11%), microvesicular steatosis (11%), macrovesicular steatosis 
(6%). Although infrequent (11%), canalicular cholestasis, together with the lobular 
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inflammatory infiltrate, containing lymphocytes and polimorphonuclear cells, showed to 
influence overall survival (p=0.03 and 0.008, respectively). The frequency and degree of 
each histological criterion assessed are shown in Table 2. 
Correlation between eight histologic features and at least one of three 
inflammatory subsets (CD8, CD45 and CD138) was found. Lobular inflammation showed 
correlation with 3 leucocytes subsets, CD8+ T cells (r=50%, p=0.008), CD138+ cells 
(r=49%, p=0.01) and CD45+ cells (r=37%, p=0.05). Bile duct epithelium degenerative 
changes and bile ducts infiltrated by lymphocytes were correlated with CD45+ cells 
(r=57%, p=0.002; r=56%, p=0.002 respectively) and CD8+ T cells (r= 45%, p=0.01; 
r=41%; p=0.01 respectively). Ductular proliferation and central perivenulitis were 
correlated with CD45+ cells (r=43%, p=0.02; r=46%, p=0.01 respectively), focal necrosis 
in parenchyma showed correlation with CD8+ T cells (r=47%, p=0.005) and CD138+ cells 
(r=45%, p=0.02). Periportal interface hepatitis and portal inflammation was correlated with 
CD8+ T cells (r=52%, p=0.005; r=40%, p=0.04 respectively) (Table 4). CD4, CD45RO and 
CD68 showed no correlation with any histological feature. An increased number of 
immunomarked for CD8 (p<0.0001) and CD45RO (p=0.01) were observed in cGVHD 
patients when compared with control group (Table 5 and Figure 1).  
NIH final diagnoses for LCGVHD showed a positive correlation with CD45+ 
(r=46, p=0.01) e CD138+/mm
2
 (r=47%, p=0.02), and also a positive correlation with the 
increase of the following liver enzyme levels: ALT (r=47; p=0.004), AP (r=38; p=0.02) and 
AST (r=33; p=0.05). 
 
DISCUSSION 
cGVHD is the most common non-relapse complication after allo-HCT.  
Although GVHD is associated with a potent antileukemia effect, cGVHD is also associated 
with significant morbidity and treatment-related mortality. cGVHD affects many organs 
and tissues, such as the skin, oral mucosa and liver, among others, resembling the 
autoimmune diseases (Hidaka et al., 2010).  
Classically, LcGVHD presents with cholestatic disorder, and liver function test 
derangement with an elevation of bilirubin and AP levels (Ma et al., 2004; Yasmineh et al., 
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1989). However, hepatitic LcGVHD differed significantly from classic liver GVHD 
regarding the pattern of hepatic serum enzymes, with higher AST and ALT levels at disease 
onset and higher AST, ALT, and ALP levels at the peak of enzymatic changes, however the 
level of bilirubin was comparable in these two situations (Ma et al., 2004). 
Our results showed correlations between some histological findings and 
increased levels of bilirubin, AP, AST and ALT. Among them, a greater number of 
histologic findings that make up the framework of hepatitic LcGVHD were correlated with 
altered liver enzymes; these are lobular lymphocytic infiltrate, lobular lymphocytic 
infiltrate with polymorphonuclear cells, bile ducts infiltrate by lymphocytes and focal 
necrosis in parenchyma. Only one characteristic findings of classic LcGVHD, decreased 
BD/ PTr, was correlated with TB, AST and ALT. Bile Ducts degenerative changes, present 
in both forms of the LcGVHD were associated with altered levels of AP. All laboratory 
liver tests studied reflected at least one of the histological hepatic changes correlated with 
diagnosis of LcGVHD. These results are in agreement with previous studies which 
demonstrated the correlation between the histopathologic and clinical diagnosis of 
LcGVHD, showing that a comprehensive assessment of the laboratorial liver tests changes 
is needed for diagnosis of liver cGVHD. (Ma et al., 2004; Strasser et al., 2000; Shulman et 
al., 1988).  
A study conducted by Duarte et al, was the first to report the prognostic value 
of histological findings for LcGVHD (Duarte et al., 2005). They showed that a high level of 
lobular inflammation and a low level of liver cell ballooning biopsy specimens were 
independent favorable prognostic factors for non-relapse mortality rate and overall survival 
(Duarte et al., 2005). In our study we found a prognostic value in two histological findings: 
canalicular cholestasis and type of lobular infiltrate. We observed a worse prognostic for 
overall survival when canalicular cholestasis was present when he lobular infiltrate was 
composed by lymphomononuclear cells. This result should be viewed with caution as the 
number of patients studied was small and the groups are unbalanced, amongst the samples, 
only 4 (11%) showed canalicular cholestasis; among biopsies with lobular inflammation 
(83%), only 9 of them (25%) were comprised for lymphomononuclear infiltrate.  
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Bile duct epithelial degenerative changes are an important histological 
diagnostic criterion of LCGVHD and its presence in classical and hepatitic LCGVHD was 
one of the most frequent histologic feature found in the studied sample (83%) and showed a 
higher correlation with the LCGVHD NIH final diagnosis (r=0.66, p<0.0001). According to 
Quaglia et al, bile duct epithelial degenerative changes culminate in bile ductal loss, which 
reinforces the histological diagnosis of LCGVHD (Quaglia et al., 2007). In agreement with 
these results, we observed a correlation of the bile ducts infiltrated by lymphocytes and 
decrease bile ducts/portal tract ratio with NIH final diagnosis of LcGVHD. Other 
histological features had a greater correlateion with NIH diagnosis for LcGVHD, such as: 
lobular inflammation, focal necrosis in parenchyma, portal inflammation, periportal 
interface hepatitis, confluent necrosis, central perivenulitis, eosinophilic portal infiltrate and 
endothelitis. These results suggest the need of observing those histological features in the 
liver biopsy assessment for diagnosis of LCGVHD, especially central perivenulitis, an 
important criterion in liver allograft rejection. Central perivenulitis, characterized by 
inflammation and necrosis around the central venules, associated with severe acute cellular 
rejection and late cellular rejection of liver allograft. Although infrequent (present in 28% 
of cases) the correlation of central perivenulitis with LcGVHD diagnosis showed that this 
histologic feature may have been underestimated in the histological context of LcGVHD.  
Fibrosis, one of the histological features that traditionally have been associated 
with chronicity of GVHD (Shulman et al., 1988; Shulman et al., 1980), showed no 
correlation with LcGVHD NIH diagnosis even though present in 67% of cases. LcGVHD is 
not a fibrogenic process (Quaglia et al., 2007). Reticulo-endothelial iron and hepatocellular 
iron showed a significant frequency among our cases, however none correlated with NIH 
LcGVHD diagnosis. Sucak et al suggest that the number of transfusions in these patients is 
a contributing factor to iron overload, although the amount of iron transfused by blood 
products per se does not explain the iron overload of the patients (Sucak et al., 2008). 
Decreased utilization of iron due to ineffective erythropoiesis, release of iron from the 
injured tissues, increased intestinal absorption of iron secondary to mucositis and GVHD, 
are other possible causes of iron overload in post-HSCT patients (Kamble et al., 2006). 
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In many target organs, such as minor salivary glands and skin, CD45+ 
lymphocytes with initially a CD4 and later a CD8 phenotype are easily identified by 
immunohistology (Sale, 2005). Our results showed the significant increase of memory T 
cells (CD45RO+) and cytotoxic T cells (CD8+) on portal tracts when compare to portal 
tracts from normal patients. No significant difference was observed between the groups for 
auxiliary T cells (CD4+). As occurs in minor salivary glands, the CD8+ T cells have 
predominance over CD4+T cells.  
 The CD8 subset showed correlation with histologic features of LCGVHD 
such as, bile ducts degenerative changes, bile ducts infiltrate by lymphocytes, portal 
inflammation, lobular inflammation and focal necrosis in parenchyma, reflecting 
topographic and qualitative participation in the inflammatory infiltrate on LcGVHD. 
Leucocytes CD45+ and CD138+, despite not being increased in LcGVHD, showed 
correlation with some histological findings and NIH final diagnosis. CD45 showed 
correlation with bile ducts degenerative changes, bile ducts infiltrate by lymphocytes, 
ductular proliferation, lobular inflammation and central perivenulite. Plasma cells 
(CD138+) were correlated with lobular inflammation and focal necrosis in parenchyma. 
The role of B cell activity in cGVHD is underscored by the observation that high plasma 
levels of BAFF (B cell activating factor), a cytokine that appears to drive B cell 
autoimmunity, were noted in patients with cGVHD (Sarantopoulos et al., 2007). Clinical 
data on the therapeutic benefit of rituximab indicate that B cells might be pathogenic in 
chronic GVHD (Cutler et al., 2006; Zaja et al., 2007). These observations, however, do not 
clarify whether B cells play a role in priming donor T cells (as antigens presenting cells) or 
function as effectors due to dysregulation of donor T-helper cells (Toubai et al., 2008). 
 Although, thirty-six biopsy samples were analyzed, and the number of 
complete portal tracts ranged from 1 to 15, a mean of 5,5 portal tracts by sample. The ideal 
number of portal tracts for liver assessment should be 10, according to Shulman et al 
(2006). The inadequate amount of portal tracts in the sample was a limitation found in this 
study; only 5 samples (14%) had 10 or more portal tracts. This limitation has been found by 
other authors (Sloane et al., 1980; Shulman et al., 1988; Quaglia et al., 2007) since samples 
are usually collected by needle biopsy, obtaining a small sample.  
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CONCLUSION  
Our results suggested that T cells CD8+ and CD45RO+ play an important role 
in the pathogenesis of liver GVHD, and that the participation of plasma cells (CD138+) 
should be further investigated. The most important histopathological features on LcGVHD 
diagnosis was the bile duct epithelium degenerative changes and  lymphocytes permeating 
the ductal epithelium, decreased bile duct/portal tract ratio, presence of lobular 
inflammation regarding the lymphomononuclear infiltrate, focal necrosis in parenchyma, 
portal inflammation and the presence of eosinophils in inflammatory infiltrate, periportal 
interface hepatitis, confluent necrosis and central perivenulitis. Significant correlation was 
found between changes in laboratorial liver tests and cGVHD diagnosis, as well as in the 
histological features that compose the criteria for NIH diagnosis of LcGVHD. Our findings 
support the view that the histological findings of the NIH Consensus are helpful in 
improving the diagnosis of GVHD. 
 
REFERENCES 
Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol 2006; 13:426-
35. 
Burt AD, Portman BC, Ferrell LD (eds). MacSween’s Pathology of the liver, 5th ed. 
Churchill Livingstone Elsevier: Philadelphia, USA, 2007.  
Cutler C, Miklos D, Kim HT et al. Rituximab for steroid refractory chronic graft-versus-
host disease. Blood 2006; 108:756–62. 
Duarte RF, Delgado J, Shaw BE, et al. Histologic Features of the Liver Biopsy Predict the 
Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. Biol Blood 
Marrow Transplant 2005; 11:805-13. 
El Sayed MH, El-Haddad A, Fahmy OA, Salama II, Mahmoud HK. Liver disease is a 
major cause of mortality following allogeneic bone marrow transplantation. Eur J 
Gastroenterol Hepatol 2004; 16: 1347–54. 
38 
 
Hidaka M, Iwasaki S, Matsui T, et al. Efficacy of bezafibrate for chronic GVHD of the 
liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 
2010; 45:912-8.  
Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ. Abnormal liver function tests 
following bone marrow transplantation: aetiology and role of liver biopsy. Eur J 
Gastroenterol Hepatol 2004; 16: 157–62. 
Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload 
manifesting as apparent exacerbation of hepatic graft versus host disease after allogeneic 
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506–10. 
Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat 
Assoc 1958; 53:457-81. 
Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association 
with treatment-related mortality and relapse. Blood 2002; 100: 406–14. 
Ma SY, AuWY, Ng IO, et al. Hepatitic graft-versus-host disease after Hematopoietic stem 
cell transplantation: Clinicopathologic features and prognostic implication. Transplantation 
2004; 77: 1252–9. 
Mantel N, Haenzel W (1958). Statistical aspects of the analysis of data from retrospective 
studies of disease. J Natl Cancer Inst 1959; 22:719-23. 
Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-
versus-host disease: initial treatment. Blood 1990; 76 :1464–72. 
McDonald GB. Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 
Years On. Hepatology 2010; 51:1450-60. 
Quaglia A, Duarte R, Patch D, Ngianga-Bakwin K & Dhillon A P. Histopathology of graft 
versus host disease of the liver. Histopathology  2007; 50: 727–38. 
Sale GE. Pathogenesis of Graft-versus-Host-Disease. Biol Blood Marrow Transplant 2005; 
11:21–23. 
39 
 
Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B cell activating factor 
(BAFF) in patients with active chronic graft versus host disease. Clin Cancer Res 2007; 13: 
6107–14. 
Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic Diagnosis of Chronic Graft-versus-
Host Disease: National Institutes of Health Consensus Development Project on Criteria for 
Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. 
Biol Blood and Marrow Transplant 2006; 12:31-47.  
Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graft-versus-
host disease after human bone marrow transplantation. Hepatology 1988; 8:463-470. 
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. 
A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–17.  
Sloane JP, Farthing MJG, Powles RL. Histopathological changes in the liver after 
allogeneic bone marrow transplantation. J Clin Pathol 1980; 33:344-50. 
Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-vs-host disease of the liver: 
presentation as an acute hepatitis. Hepatology 2000; 32:1265-1271. 
Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long term marrow 
transplant survivors. Blood 1999; 93: 3259–66. 
Sucak GT, Yegin ZA , Özkurt ZN, Akı SZ, Karakan T and Akyol G. The role of liver 
biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload 
underestimated? Bone Marrow Transplant 2008; 42: 461–67. 
Tomas JF, Pinilla I, Garcia-Buey ML, et al. Long term liver dysfunction after allogeneic 
bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow 
Transplant 2000; 26: 649–55. 
Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best 
Pract Res Clin Haematol 2008; 21: 101–117. 
Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for 
classification of late acute and chronic GVHD. Blood 2009; 114:702-8. 
40 
 
Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self-tolerance and 
autoimmunity. Nat Immunol 2010; 11:7–13. 
Yasmineh WG, Filipovich AH, Killeen AA. Serum 5' nucleotidase and alkaline 
phosphatase—highly predictive liver function tests for the diagnosis of graft-versus-host 
disease in bone marrow transplant recipients. Transplantation 1989; 48: 809–14. 
Zaja F, Bacigalupo A, Patriarca F et al. Treatment of chronic GVHD with rituximab: a 
GITMO study. Bone Marrow Transplant 2007; 40: 273–277. 
 
ACKNOWLEDGMENTS 
This paper was supported by the Coordination for Higher Level Graduates 
Improvement (CAPES) and Research and Extension Support Foundation (FAPESP) n° 
2006/59917-7 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
TABLES 
Table 1. Patients’ clinical characteristics.   
Variable n = 36  
Age, median (range) 29.5 (12-59) 
Male: female, n (%) 21 (58) : 15 (42) 
Disease, n (%)   
    CML 24 (66.7) 
    ALL 4 (11) 
    SAA 3 (8.3) 
    AML 2 (5.6) 
    MDS 2 (5.6) 
    PNH 1 (2.8) 
Conditioning regimen, n (%)  
    BU + CY 31 (86.1) 
    BU + VP + CY 3 (8.3) 
    CY + TBI 1 (2.8) 
    CY 1 (2.8) 
Graft, n (%)  
    Bone marrow 21 (58.3) 
    Peripheral blood  15 (41.7) 
GVHD prophylaxis, n (%)  
    CsA/MTX 32 (88.9) 
    CsA/Corticosteroid 4 (11.1) 
Serum liver tests, n (%)*  
    Total Bilirubin 16 (44.4) 
    Aspartate transaminase 27 (75) 
    Alanine transaminase 26 (72.2) 
    Alkaline phosphatase 34 (94.4) 
Mean Follow-up, median (range) ** 122 (8-180) 
ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, 
myelodysplastic disorder syndrome; AML, acute myelogenous leukemia; SAA, severe 
aplastic anemia; PNH, paroxysmal nocturnal hemoglobinuria; VP, VP-16 Etoposide; BU, 
Busulfan; CY, cyclophosphamide; TBI, total body irradiation; CsA, Cyclosporin A; MTX, 
Methotrexate.  
* Serum level > 2 times above the upper normal limit. 
** Follow-up in months. 
 
Table 2. Histological features assessed in liver. 
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Table 2. Histological features assessed in liver. 
Histological feature Grading Frequency, n (%) 
Bile duct epithelium 
degenerative 
changes** 
1 = Absent 6 (16.7) 
2 = Focal Involvement (few ducts) 20 (55.6) 
3 = Diffuse Involvement (most ducts) 10 (27.8) 
Lymphocyte 
exocytosis through 
bile ducts* 
1 = Absent 13 (36.1) 
2 = One or more lymphocytes in one bile duct 18 (50.0) 
3 = lymphocytes in more than 1 bile duct 3 (8.3) 
4 = lymphocytes in all bile ducts 2 (5.6) 
Periductal lymphoid 
aggregates*  
1 = Absent 36 (100) 
2 = Present 0 
Periductal fibrosis* 
0 = Absent 32 (88.9) 
1 = Focal Involvement (few ducts) 4 (11.1) 
2 = Diffuse Involvement (most ducts) 0 
Ductular reaction* 
1 = Absent 32 (88.9) 
2 = Mild and focal (up to six ductules < 50% of portal tracts) 4 (11.1) 
3 = More than 6 ductules in < 50% of portal tracts or up to 6 
      ductules in > 50% of portal tracts 
0 
 4 = More than 6 ductules in > 50% of portal tracts 0 
Bile duct/portal tract 
ratio*** 
1 = 1,8 - 0,9 31 (86.1) 
2 = 0,8 - 0,5 5 (13.9) 
3 = 0,4 - 0,1 0 
4 = <0,1  0 
Canalicular 
cholestasis* 
1 = Absent 32 (88.9) 
2 = Occasional identified plugs 2 (5.6) 
3 = Easily identifiable bile plugs in most centrilobular areas 2 (5.6) 
4 = Widespread canalicular cholestasis 0 
Intrahepatocytic  
cholestasis*** 
1 = Absent 31 (86.1) 
2 = Present 5 (13.9) 
Chronic 
cholestasis** 
1 = Absent 35 (97.2) 
2 = Present 1 (2.8) 
Portal 
inflammation*** 
1 = Absent (scarce lymphocytes)  2 (5.6) 
2 = Mild, some or all portal tracts 16 (44.4) 
3 = Moderate, some or all portal tracts 14 (38.9) 
4 = Moderate/marked, all portal tracts 3 (8.3) 
5 = Marked, all portal tracts 1 (2.8) 
Type of portal 
inflammation  
1 = lymphomononuclear  9 (25) 
2 = lymphocytes and polymorphonuclear cells 25 (69.4) 
Periportal interface 
hepatitis*** 
1 = Absent  18 (50) 
2 = Mild (focal, few portal tracts) 13 (36.1) 
3 = Mild/Moderate (focal, most portal tracts)  1 (2.8) 
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4 = Moderate (continuous around <50% of tracts or septa) 2 (5.6) 
5 = Severe (continuous around >50% of tracts or septa) 2 (5.6) 
Apoptosis* 
1 = Absent 22 (61.1) 
2 = One apoptotic body per 10X objective 13 (36.1) 
3 = Two to four apoptotic bodies per 10X objective 1 (2.8) 
4 = More than four apoptotic bodies per 10X objective 0 
Focal lobular 
necrosis*** 
1 = Absent 9 (25) 
2 = Few foci 12 (33,3) 
3 = Several Foci 15 (41.7) 
Confluent 
necrosis*** 
1 = Absent 24 (66.7) 
2 = Focal confluent necrosis 7 (19.4) 
3 = Bridges of confluent necrosis 5 (13.9) 
Liver cell 
ballooning* 
1 = Absent 11 (30.6) 
2 = Occasional ballooned hepatocytes usually with centrilobular 
location 
13 (36.1) 
3 = Easily identifiable ballooned hepatocytes in most centrilobular 
areas 
11 (30.6) 
4 = Widespread liver cell ballooning 1 (2.8) 
Fibrosis*** 
1 = Absent 12 (33.3) 
2 = Portal fibrosis 20 (55.6) 
3 = Portal–portal fibrous septa 4 (11.1) 
4 = Predominance of areas with incomplete nodules or septa 0 
5 = Predominance of nodules / cirrhosis 0 
Macrovesicular 
steatosis*** 
0 = Until 5% parenchyma 34 (94.4) 
1 = 5-33% parenchyma 2 (5.6) 
2 = 34-66% parenchyma 0 
3 = > 67% parenchyma 0 
Microvesicular 
steatosis*** 
0 = Absent 32 (88.9) 
1 = Focal 4 (11.1) 
2 = Form contiguous sheets 0 
Lobular 
inflammation***  
0 = Absent 6 (16,7) 
1 = Mild 15 (41.7) 
2 = Moderate 14 (38.9) 
3 = Marked  1 (2.8) 
Type of lobular 
inflammation  
1 = Lymphomononuclear  9 (25) 
2 = Lymphocytes and polymorphonuclear cells 21 (58.3) 
Hepatocellular iron  
Accumulation*** 
0 = Absent or hardly discernible at 400X 13 (36.1) 
1 = hardly discernible at 250X and  easily identifiable at 400X 7 (16.7) 
2 = Discrete granules easily identifiable at 100X 5 (13,9) 
3 = Discrete granules easily identifiable at 25X 8 (22.2) 
4 = Visible masses at 10X 3 (8.3) 
Reticuloendothelial 
iron 
1 = Absent 6 (16.7) 
2 = Present 30 (83.3) 
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Endotheliitis*  
1 = Absent 25 (69.4) 
2 = Focal  10 (27.8) 
3 = Moderate  1 (2.8) 
4 = Diffuse  0 
Central perivenulitis 
1 = Absent 25 (71.4) 
2 = Present 10 (28.6) 
Eosinophilic portal 
inflammation 
1 = Absent 28 (82.4) 
2 = Present 6 (17.6) 
Arteritis* 
1 = Absent 35 (97.2) 
2 = One artery  1 (2.8) 
3 = More than one artery  0 
4 = All arteries 0 
*Histologic feature assessment according Quaglia et al., 2007. 
** Histologic feature assessment according Histopathology forms of Shulman et al., 2006.  
***Histologic feature assessment according Burt et al., 2007. 
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Table 3. Correlation of the histological features analyzed with hepatic enzyme levels and 
histologic L-GVHD diagnosis. 
 Correlation % (p) 
Histologic features TB ALT AST AP LcGVHD  
Bile duct/portal tract ratio 33 (0.04) 37 (0.02) 41 (0.01) NC 40 (0.01) 
Lobular inflammation  NC NC 35 (0.03) 52 (0.001) 51 (0.001) 
Lobular inflammation Type  NC NC 45 (0.006) 42 (0.01) 46 (0.004) 
Bile ducts infiltrated by lymphocytes NC 53 (0.001) 46 (0.004) NC 43 (0.01) 
Focal necrosis in parenchyma NC NC NC 44 (0.007) 51 (0.001) 
Bile duct epithelium degenerative 
changes 
NC NC NC 36 (0.03) 66 (<0.0001) 
Periportal interface hepatitis NC NC NC 35 (0.03) 39 (0.01) 
Portal inflammation NC NC NC NC 54 (0.001) 
Confluent necrosis NC NC NC NC 42 (0.01) 
Central perivenulitis NC NC NC NC 36 (0.03) 
Eosinophilic Portal inflammation NC NC NC NC 36 (0.03) 
Endothelitis NC NC NC NC 33 (0.04) 
TB, total bilirubin; ALT, alanine transaminase; AST, Aspartate transaminase; AP, alkaline 
phosphatase; NC, No correlation. 
 
Table 4. Correlation between histological features of liver cGVHD and leucocytes subsets. 
 
 Correlation % (p) 
Histologic features CD8 CD45 CD138 
Bile duct epithelium degenerative changes 45 (0.01) 57 (0.002) NC 
Bile ducts infiltrated by lymphocytes 41 (0.01) 56 (0.002) NC 
Ductular reaction NC 43 (0.02) NC 
Portal inflammation 40 (0.04) NC NC 
Periportal interface hepatitis 52 (0.005) NC NC 
Lobular inflammation  50 (0.008) 37 (0.05) 49 (0.01) 
Focal necrosis in parenchyma 47 (0.005) NC 45 (0.02) 
Central perivenulitis NC 46 (0.01) NC 
NC, No correlation. 
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Table 5. Leucocytes subsets in the liver portal tract of patients with cGVHD and control 
group.  
 
 
With GVHD   Control group  
Mean* St Deviation* N  Mean* St Deviation* N p 
CD8 2397.61 1358.19 27  839.29 440.53 17 <0.0001 
CD45RO 2208.11 1143.50 16  1247.65 902.18 18 0.01 
CD45 2915.45 2017.86 28  2077.14 1089.96 19 0.1 
CD4 1516.92 935.91 27  1219.15 711.58 20 0.2 
CD68 963.08 629.07 21  780.80 540.05 19 0.3 
CD138 362.12 485.54 25  261.23 248.30 15 0.4 
*Cells/mm
2 
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FIGURES 
 
Figure 1. Immunostained liver sections targeting for CD4, CD8, CD45, CD45RO, CD68 and 
CD138 in control group- and cGVHD patients. Original magnification x400. 
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ABSTRACT 
Background: Chronic GVHD (cGVHD) after hematopoietic stem cell transplantation 
(HSCT) is a multisystem alloimmune and autoimmune disorder characterized by immune 
dysregulation, immunodeficiency, and impaired organ function. The aim of this study was 
to compare mononuclear cell subsets in minor salivary gland (MSG) and liver samples of 
patients with cGVHD after HSCT and to identify MSG histological changes that might be 
predictive of severity in the liver involvement by GVHD. 
Methods: Liver and MSG biopsies of 36 cGVHD patients were studied. The patients had 
undergone ablative HLA- matched- sibling HSCT. Histological sections were stained for 
H&E and immunohistochemical technique targeting CD45, CD4, CD8, CD138, and CD68. 
Digital images were analyzed through Imagelab 2000® software.  
Results: Clinical changes resulting from cGVHD in the oral cavity were prior or, at least, 
simultaneous, to clinical and laboratorial liver changes. Diagnosis of liver cGVHD 
categories 3 or 4 from NIH consensus were correlated with serum levels > 2 times above 
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the upper normal limit of ALT, AST and AP. A positive correlation was found between the 
relative proportion of CD4, CD8, and CD45 immuno-labeled cells in MSG and liver biopsy 
samples. Higher numbers of CD45+ and CD138+ cells/mm
2
 in portal tract correlated with 
NIH diagnoses 3 or 4 for liver cGVHD. Higher relative numbers of CD45+ and lesser of 
CD8+ cells in MSG, were found to be predictive of severity in liver GVHD histological 
changes.   
Conclusion: MSG mononuclear infiltrates mirror those of liver in cGVHD. Considering 
the set of clinical and laboratory findings, MSG biopsies, whicht are easily obtained, could 
help estimate hepatic changes in cGVHD patients.                                                                                                                  
 
INTRODUCTION 
Chronic graft-versus-host disease (cGVHD) is a multiorgan disorder with 
features of immunodeficiency and autoimmunity [1]. This disorder can affect any major 
organ system, but most commonly affects skin, oral-, vaginal-, and conjunctival mucosa, 
salivary and lacrimal glands, and the liver [2]. Clinically, cGVHD symptoms resemble 
those of autoimmune- and other immunologic disorders, such as scleroderma, Sjögren 
syndrome, primary biliary cirrhosis, wasting syndrome, bronchiolitis obliterans, immune 
cytopenias, and chronic immunodeficiency [3, 1]. 
Eighty per cent of patients with liver involvement by GVHD have increased 
serum levels of alkaline phosphatase, bilirubin and aminotransferases [5]. Histologically, 
typical liver GVHD is characterized by bile duct damage, portal lymphocytic infiltrate, and 
centrilobular necrosis. Other features include marked lobular hepatitis, hepatocyte unrest, 
and sinusoidal inflammation with perivenular necroinflammatory foci. Intrahepatic bile 
ducts injury begins with degenerative changes, followed by multifocal necrosis of isolated 
epithelial cells, nuclear pleomorphism, atrophy, and finally, the disappearance of ducts [5-
7]. Late changes such as cholestasis, biliary cirrhosis, and chronic hepatitis may develop 
[8,9].  
Common clinical oral findings in cGVHD include erythema, mucosal 
inflammation and atrophy, lichenoid changes, mucoceles, hyperkeratotic plaques, perioral 
fibrosis, and infections related to hiposalivation [10-12]. The histological presentation of 
50 
 
salivary glands cGVHD includes lymphohistiocytic infiltrate on the glandular parenchyma 
and periductal tissue, with or without plasma cells, exocytosis of lymphocytes (without 
neutrophils) into lobular ducts and acini, and subsequent acinar destruction with fibrosis 
[11, 13-16]. In additon, the ducts of the minor salivary glands (MSG) become damaged, 
displaying epithelial cell apoptosis, ectasia, atrophy, and peripheral fibrosis [17]. 
Given the close similarities between cGVHD and autoimmune diseases, mainly 
primary biliary cirrhosis, and Sjogren's syndrome, a long-standing hypothesis has been 
postulated in that cGVHD results from pathogenic effects mediated by ‘‘autoimmune’’ T 
cells that recognize donor antigens or shared antigens of the donor and recipient rather than 
alloantigens of the recipient [1]. Primary biliary cirrhosis (PBC), such as cGVHD, is a 
multisystem disease, that involves lacrimal and salivary glands in 70-100% of patients. 
Damage to small intrahepatic bile ducts is characteristic of early PBC [18]. Of the patients 
with PBC, 58% to 93% have histologic abnormalities of the salivary glands, whereas 33% 
to 64% have abnormal sialometry or sialograms [19]. Although the clinical manifestations 
of salivary gland injury are similar in cGVHD and Sjögren syndrome (SS) [20], differences 
exist. SS and cGVHD share a lympho-plasmacytic peri-ductal and intralobular 
inflammatory infiltrate, with varying degrees of acinar atrophy and fibrosis. However, in 
SS, the peri-ductal cell infiltrate is more pronounced, and there is a predominance of CD4 
versus CD8 T cells, whereas in cGVHD there is a predominance of CD8 T lymphocytes, 
with macrophages and plasma cells [21].  
The liver is an exocrine glandular structure; similar to salivary and lacrimal 
glands, and has an acinar-ductular anatomy [18]. Both, liver and salivary glands have a 
common developmental endoderm origin and, express the HLA antigen, required for 
immune recognition [22, 23]. The ductal epithelium from salivary glands and bile ducts has 
a high density of histocompatibility complex antigens, so that, after HSCT, they become the 
target of the donor T cells [22, 23].   
According to Duarte et al. [24], lobular inflammation and hepatocytes 
ballooning in liver samples, were considered favorable prognostic factors for non-relapse 
mortality and overall survival. Pavletic et al. [25] observed, on clinical grounds, that the 
impairment of the oral cavity was a factor in determining prognosis for survival in patients 
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with cGVHD. Considering that minor salivary gland samples are easily obtained and the 
significant frequency of oral and hepatic cGVHD, the impact as a predictor of treatment 
outcome for HSCT [24, 25], and the structural- and histological relationship between liver 
and salivary glands [18], the correlation between the histological findings of the salivary 
glands and liver in cGVHD may be of great importance. 
Our goal was to compare mononuclear cells subsets in MSG and liver samples 
of patients with cGVHD after HSCT, and investigate whether there is any MSG 
histological change that might be predictive of the severity in the liver involvement by 
GVHD.  
 
PATIENTS AND METHODS 
The files of the Bone Marrow Transplantation unity of UNICAMP University 
Hospital during the period of 1994-2006 were searched, and 245 patients were found to be 
clinically diagnosed with cGVHD. Amongst these, 189 patients presented clinic signals 
suggestive of oral or liver GVHD; 49 patients shared oral and liver clinic symptoms/signals 
suggestive of cGVHD and had, at least, one MSG and liver biopsy sample collected for 
diagnosis purposes. Patients with other causes for liver dysfunction, and liver or MSG 
biopsies with insufficient amount of paraffin- embedded tissue for histological new cuts, 
were ruled out. After these evaluations, 36 patients were included in this study. They had 
undergone ablative HLA- matched- sibling HSCT. The patients’ clinical data were 
retrieved from medical charts and are summarized in table 1. 
The biopsy specimens were obtained on the same day that clinical signs and 
symptoms suggestive of cGVHD were detected. Liver biopsies were performed when 
laboratory abnormalities were suspected for cGVHD. The MSG samples were collected 
from the lower inner lip, approximately 10 mm beneath the vermilion border, through a 4 
mm-punch, under local anesthesia. Liver biopsy was performed through percutaneous 
needle biopsy. The tissue specimens were fixed in 10% buffered formalin and paraffin- 
embedded for histological purposes. 
Histological study  
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Both, liver and MSG histological sections were stained with hematoxylin-eosin 
and Masson’s trichrome for fibrosis evaluation. Liver samples were also stained for 
reticulin (to assess fibrosis and loss of architecture) and iron (Perl’s staining). 
All specimens were assessed for histological cGVHD diagnosis according to 
the National Institutes of Health (NIH) consensus pathology working group criteria 
(Shulman et al., 2006), to wit: 1- no GVHD, 2- possible GVHD, 3- consistent with GVHD 
(equivalent to “favor,” “suggestive of,” or “probable”), or 4- definite (unequivocal) GVHD.  
Immunohistochemical study 
Four micrometer- thick sections were obtained, dewaxed and rehydrated. The 
primary monoclonal antibodies used were: CD4, clone OPD4 at a 1:100 dilution; CD8, 
clone C8/144B,  at a 1:200 dilution; CD45, clone 2B11+PD7/26, at a 1:500 dilution; CD68, 
clone KP1, at a 1:700 dilution; CD138, clone MI15,  at a 1:200 dilution, all from DAKO 
(Dako Cytomation, Carpinteria, CA, USA). The epitope retrieval was performed through a 
steamer with citrate buffer. The EnVision polymer (Dako Cytomation) was used as a 
reaction amplifier, and staining followed the supplier’s recommendation. Visualization of 
the antibody complex was achieved using 3,3-diaminobenzidine tetrahydrochloride (Sigma, 
St Louis, Missouri, USA) according to the manufacturer’s instructions. Sections were 
counterstained with Mayer hematoxylin. Unsatisfactory sections were excluded and the 
procedures were repeated. Appropriate negative and positive controls were included in each 
essay. 
The quantitative analysis for each antibody was accomplished as follows: 
digital images were obtained through a Power Shot A630 Canon camera connected to a 
Nikon Eclipse E200 microscope, under a 40x objective. Regarding liver samples, the 
number of captured microscopic fields ranged with the size and amount of portal tracts by 
liver samples. Thus, enough fields were photographed in order to sufficiently analyze 10 
complete portal tracts. For MSG samples, 10 blindly and randomly fields were captured. 
Digital images were analyzed through Imagelab 2000® (Image analysis system, Diracom, 
Sao Paulo, Brazil); the software was used for cell quantification and portal tracts area 
measurements. The mean number of the immunomarked cells/mm
2
 by portal tract in liver 
or by specimen in MSG was used for statistical analysis.  
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Statistical Analysis 
The main tests applied were the Spearman correlation and multiple regressions 
for modeling the relationship between a scalar variable (NIH consensus schema) and MSG 
subset cells. Statistical significance level was set at p<0.05. Statistical analysis was 
performed using Statistical Package for the Social Sciences (SPSS) for Windows 14.0.  
 
RESULTS 
Seventy two biopsy samples were analyzed (36 MSG and 36 liver specimens). 
The biopsy day post-HSCT ranged from 77 to 2380 for liver (median 257) and from 77 to 
1681 (median 189) for MSG. Thus, for one same patient, the day MSG and liver biopsies 
were collected, did not necessarily coincide. Twenty-one patients had GSM biopsy 
collected before liver biopsy, considering these biopsies, the difference between the day 
post-HSCT of GSM and liver sample collect ranged from 5 to 308 days (median 112). 
Seventy two percent of cases had a previous clinical diagnosis of oral cGVHD at the time 
of liver biopsy. Regarding skin, eyes and gastrointestinal tract, only 25, 22 and 3% of cases, 
respectively, had a previous clinical diagnosis of cGVHD at the time of liver biopsy (Table 
2).  
Positive correlation was found between CD4+ (r=85%, p<0.0001), CD8+ 
(r=60%, p= 0.002), and CD45+ (r= 46%, p=0.01) cells/mm
2
 in MSG and liver biopsy 
samples (Table 3 and Figure 1).  
Liver NIH diagnoses 3 or 4 were correlated with serum levels > 2 times above 
the upper normal limit of ALT (r=47%, p=0.0004), AST (r=33%, p = 0.05) and AP 
(r=38%, p=0.02). Through multiple regression test,  having NIH schema as dependent 
variable, a predictive value of CD45+ and CD8+ cells/mm
2
 was found in MSG for NIH 
liver GVHD diagnosis (p= 0.01 and p= 0.02, respectively), taking the model of class 3 or 4 
of the NIH schema as a reference, to wit: when the number of CD45 positive-cells was 
higher than 1000/mm
2
, the chance of the specimen to be part of NIH critical group was 
higher whereas for CD8, the fewer the cells, the greater the specimen chance to be in the 
NIH schema ≥3.  
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DISCUSSION 
Chronic GVHD resembles autoimmune and other immunologic disorders, such 
as scleroderma, Sjögren syndrome, primary biliary cirrhosis, and bronchiolitis obliterans [1, 
3]. Skin, mouth, liver, eyes and gut, in decreasing order, are the most frequently involved 
sites [26]. In our cohort, we observed that in 72% of the cases, the diagnosis of oral 
cGVHD had been suggested before liver biopsy was collected. This draws attention to the 
role of the mouth as a herald site to the development of the disease. Although the skin is 
considered to be the most commonly affected organ [26], only 25% of cases had a previous 
diagnosis of cGVHD in skin at the time of liver biopsy. In fact, 72% to 83% of patients 
with cGVHD showed oral involvement [11]. Our data indicate that the clinical changes 
resulting from cGVHD in the oral cavity occur earlier or, at least, simultaneously, to 
clinical and laboratorial liver changes.  
The pathogenesis of cGVHD is poorly understood [2, 12]. Donor-derived 
immunocompetent T cells have been shown to react against host tissue after allo-HSCT, 
directly or through exaggerated inflammatory responses [27, 28]. Current concepts 
regarding the pathogenesis of cGVHD include: 1- the persistence of alloreactive T cells, 2- 
a Th1–Th2 shift of the cellular immune response (cGVHD seems to be mediated 
prominently by the Th2 cytokine response), 3- a failure of control by regulatory T cells 
and/or impaired negative selection of T cells in the thymus, 4- replacement of antigen 
presenting cells (APC) of the host by APCs of the donor leading to indirect antigen 
presentation of allo-antigens, 5- an increasing role of B cells producing auto- and allo-
antibodies against the host,  and 6- nonspecific mechanisms of chronic inflammation 
leading to fibrosis of involved organs. 
Some studies have reported that salivary gland changes are histologically 
characterized by the presence of lymphocyte infiltrate, with slight predominance of CD8+ 
versus CD4+ T cells, in the glandular parenchyma and periductal tissue [3, 14, 17]. With 
respect to liver, in a murine model for GVHD, the percentage of CD4+ cells (29%) was 
seen to be 3 times that of CD8+ cells (11%) and 30% of the cells were positive for Mac-1, a 
differentiation marker of macrophages, large granular lymphocytes, and natural  killer cells 
[30]. In our samples there was a predominance of CD8+ T cells over CD4+ T cells in both 
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organs, liver and MSG. Despite the small size of our sample, it was possible to compare 
mononuclear cells subsets in both organs (MSG and liver) and to screen MSG histological 
changes predictive for liver GVHD diagnosis. We found a positive correlation between 
lymphocytes subsets in liver and MSG. The strongest correlation was related to CD4+ T 
cells (85%), however CD8+ T cells were also correlated (60%). No correlation was found 
for macrophages (CD68+ cells) population.   
The primary target of liver GVHD is the bile duct epithelium in different 
species of experimental animals [17]. The bile ducts are destroyed by an immune-mediated 
reaction, directed against the histocompatibility antigens. The small intrahepatic bile ducts 
are the most affected, as they contain the highest density of histocompatibility complex 
antigens [18]. Similarly, in MSG cGVHD, ducts appear to be the first target [14], possibly 
due to their high expression of histocompatibility antigens as well as the accessibility of the 
salivary glands to pathogenic lymphocytes [23]. 
Takahashi et al [31] pointed to the participation of CD4+ and CD8+ T 
lymphocytes in the destructive processes of intrahepatic bile ducts by observation of these 
cells either in proximity of- or within the degenerated cholangioepithelium.  We found an 
important participation of CD4+ and CD8+ T cells in the liver inflammatory infiltrate; 
however it was not possible to discern their specific targets due to the high cellular density 
throughout the portal tract in most cases. On the other hand, within MSG samples, a 
cellular CD4+ and CD8+ infiltrate was observed around ducts, nevertheless, in most ducts, 
the cells that infiltrated the epithelium were the CD8 + T cells . Therefore, the involvement 
of CD8+ T cells in the damage of the salivary ducts appears to be more significant than that 
of CD4+ cells.  
The relationship between CD8 and CD45 positive cells in MSG and the liver 
GVHD diagnosis (through NIH schema) suggests that the growing number of CD45+ cells 
indicate an active and progressive inflammatory status culminating with the involvement of 
other organs. In contrast CD8+ T cells in MSG, in this process stage, have an inverse 
participation in the diagnosis of liver GVHD.  
The correlation of NIH schema with serum levels of ALT, AST and AP > 2 
times above the upper normal limit confirmed the association of NIH schema for 
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histopathological diagnosis of liver GVHD with the clinical abnormalities on which the 
decision to collect liver biopsy was based.  
Briefly, the cell density of CD8+ and CD45+ lymphocytes subsets in MSG 
samples had a predictive value for GVHD diagnosis in liver, which points to the 
importance of a histological evaluation of MSG. There is a certain risk in obtaining liver 
biopsies, especially in patients who have been submitted to HSCT, however this does not 
happen with MSG. Thus, salivary glands biopsies could help estimate hepatic changes in 
cGVHD patients.  
 
CONCLUSION 
Liver mononuclear infiltrates mirror those of MSG in cGVHD. Considering the 
set of clinical and laboratory findings, MSG biopsies which are easily obtained, could help 
estimate hepatic changes in cGVHD patients. 
 
CONFLICT OF INTERESTS 
The authors declare that they have no conflicting interests. 
 
ACKNOWLEDGEMENTS  
 The authors thank Mr. Adilson Abilio Piaza for his help in taking 
photomicrographs. This paper was supported by the Coordination for Higher Level 
Graduates Improvement (CAPES) and São Paulo Research Fundation (FAPESP).  
 
REFERENCES  
1. Teshima T, Wynn TA, Soiffer RJ, Matsuoka KI, Martin PJ. Chronic Graft-versus-Host 
Disease: How Can We Release Prometheus? Biol Blood and Marrow Transplant 2008; 
14:142-50. 
2. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC. Oral graft-versus-host 
disease. Oral Dis 2008; 14: 396-412. 
57 
 
3. Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from 
the International Consensus Conference on clinical practice in cGVHD. Clin Oral 
Investig 2011; 15:27-39. 
4. Ferrara JL, Deeg HJ.  Graft-versus-host disease. N Engl J Med 1991; 324:667-74. 
5. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-versus-host disease of the 
liver: presentation as an acute hepatitis. Hepatology 2000; 32:1265–71. 
6. Fujii N, Takenaka K, Shinagawa K, et al. Hepatic graft-versus-host disease presenting as 
an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone 
Marrow Transplant 2001; 27:1007–10. 
7. McDonald GB. Review article: management of hepatic disease following 
haematopoietic cell transplant. Aliment Pharmacol Ther 2006; 24: 441 – 452. 
8. Knapp AB, Crawford JM, Rappeport JM, Gollan JL. Cirrhosis as a consequence of graft 
versus host disease. Gastroenterology 1987; 92: 513-9. 
9. Berman MD, Raben L, O’Donnell J, Gratwohl AA, Graw RG, Deisseroth AB, Jones 
EA. The liver in long term survivors of marrow transplant – chronic graft host disease. J 
Clin Gastroenterol 1980; 2: 53 – 63. 
10. Woo SB, Lee JS, Schubert MM. Graft-vs-host disease. Crit Rev Oral Biol Med 1997; 8: 
201–16. 
11. Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am 2008; 
52:79-109. 
12. Filipovich AH, Weisdorf D, Pavletic S et al.  National Institutes of Health consensus 
development project on criteria for clinical trials in chronic graft-versus-host disease: I. 
Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 
945–956. 
13. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic Diagnosis of Chronic Graft-
versus-Host Disease: National Institutes of Health Consensus Development Project on 
Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working 
Group Report. Biol Blood Marrow Transplant 2006; 12:31-47.  
58 
 
14. Soares AB, Faria PR, Magna LA, et al. Chronic GVHD in minor salivary glands and 
oral mucosa: histopathology and immunohistochemical evaluation of 25 patients. J Oral 
Pathol Med 2005; 34:368-73. 
15. Alborghetti MR, Correa MEP, Adam RL, Coracin FL, Souza CA, Cintra ML. Late 
effects of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med 
2005; 34: 486-93. 
16. Sale GE, Gallucci BB, Schubert MM, et al. Direct ultrastructural evidence of 
targetdirected  polarization by cytotoxic lymphocytes in lesions of human graft-vs-host 
disease. Arch Pathol Lab Med 1987; 111: 333–6. 
17. Sale GE. Pathogenesis of graft-versus-host-disease. Biol Blood Marrow Transplant 
2005; 11: 21-3. 
18. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome 
with features of chronic graft-versus-host disease. Lancet 1980; 1: 1166-8. 
19. Ebert EC. Gastrointestinal and Hepatic Manifestations of Sjogren Syndrome. J Clin 
Gastroenterol 2012; 46: 25–30. 
20. Imanguli MM, Atkinson JC, Mitchell SA et al. Salivary gland involvement in chronic 
graft-versus-host disease: prevalence, clinical significance, and recommendations for 
evaluation. Biol Blood Marrow Transplant 2010; 16: 1362-9. 
21. Harada M, Niho Y, Oka M. A comparison of glandular involvement between chronic 
graft-versus-host disease and Sjögren syndrome. Int J Oral Maxillofac Surg 1996; 25: 
298-307. 
22. Lautenschlager I, Häyry P. Expression of the major histocompatibility complex antigens 
of differents liver cellular components in rat and man. Scan J Immunol 1981; 14:421-26. 
23. Nagler RM, Nagler A. The molecular basis of salivary gland involvement in graft--vs.--
host disease. J Dent Res. 2004; 83: 98-103. 
24. Duarte RF, Delgado J, Shaw BE et al. Histologic Features of the Liver Biopsy Predict 
the Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. Biol 
Blood Marrow Transplant 2005; 11: 805-13. 
59 
 
25. Pavletic SZ, Smith LM, Bishop MR, et al. Prognostic Factors of Chronic Graft-Versus-
Host Disease After Allogeneic Blood Stem-Cell Transplantation. Am J Hematol 2005; 
78: 265-74. 
26. Flowers MED, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host 
disease after transplantation of peripheral blood stem cells versus bone marrow in 
allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-
419. 
27. Ferrara JL, Reddy P. Pathophysiology of graft-versus host disease. Semin Hematol 
2006; 43: 3–10.  
28. Martin RW, Farmer ER, Altomonte VL et al. Lichenoid graft-vs-host disease in an 
autologous bone marrow transplant recipient. Arch Dermatol 1995; 131: 333-5. 
29. Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an 
enigma. Korean J Hematol. 2011; 46: 80-7.  
30. Howell CD, De Victor D, Li J, Stephens J, Giorno RC. Liver T cell subsets and adhesion 
molecules in murine graft-versus-host disease. Bone Marrow Transplant. 1995; 16: 139-
45. 
31. Takahashi T, Miura T, Nakamura J, et al. Plasma cells and the chronic nonsuppurative 
destructive cholangitis of primary biliary cirrhosis. Hepatology 2012; 55: 846-55. 
 
 
 
 
 
 
 
 
 
60 
 
TABLES 
Table 1. Patients’ (N=36) data   
Variable N (%)  
Age, median (range) 29.5 (12-59) 
Male sex 21 (58) 
Disease   
    CML 24 (66.7) 
    ALL 4 (11) 
    SAA 3 (8.3) 
    AML 2 (5.6) 
    MDS 2 (5.6) 
    PNH 1 (2.8) 
Conditioning regimen  
    BU + CY 31 (86.1) 
    BU + VP-16 + CY 3 (8.3) 
    CY + TBI 1 (2.8) 
    CY 1 (2.8) 
Graf  
    Bone marrow 21 (58.3) 
    Peripheral blood  15 (41.7) 
    After  donor lymphocyte infusion 5 (13.9) 
GVHD prophylaxis  
    CsA/MTX 32 (88.9) 
    CsA/Corticosteroid 4 (11.1) 
Mean Follow-up, median (range) * 122 (8-180) 
ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, 
myelodysplastic syndrome; AML, acute myelogenous leukemia; SAA, severe aplastic 
anemia; PNH, paroxysmal nocturnal hemoglobinuria; VP-16, Etoposide; BU, Busulfan; 
CY, cyclophosphamide; TBI, total body irradiation; CsA, Cyclosporin A; MTX, 
Methotrexate.  
* Follow-up in months. 
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Table 2. Clinical signs of cGVHD in oral cavity, gastrointestinal tract, skin, and eyes at the 
time of liver biopsy obtaining. 
Target organ Frequency (%) 
Skin 9 (25) 
Oral cavity 26 (72) 
Eyes 8 (22) 
Gastrointestinal tract 1 (3) 
 
Table 3. Correlation between liver and minor salivary glands mononuclear subsets. 
 Correlation (p) Liver* Salivary Gland* 
CD4 85% (< 0.0001) 1516.92 ( 936) 203.28 ( 294) 
CD8 60% (0.002) 2397.61 ( 1358) 488.05 ( 436) 
CD68 NS 963.08 ( 629) 259.33 ( 242) 
CD45 46% (0.01) 2915.45 ( 2017) 667 ( 772) 
CD138 NS 362.12 ( 485) 307.36 ( 271) 
Pearson’s correlation; NS, not significant; *Mean (standard deviation) of cells/mm2  
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FIGURES 
 
Figure 1. Immunostained sections of minor salivary glands (MSG) and liver of cGVHD patients. A: 
MSG section immunostained for CD4; B: Liver section immunostained for CD4; C: MSG section 
immunostained for CD8; D: Liver section immunostained for CD8; E: MSG section immunostained 
for CD45; F: Liver section immunostained for CD45. Original magnification x400.  
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CONCLUSÃO 
 
1) Os aspectos histológicos em glândulas salivares menores (GSM) e fígado apresentam 
correlação entre si.  
 Há correlação positiva entre a quantia de linfócitos T CD4+, CD8+ e CD45+/mm2 em 
glândulas salivares e fígado. 
 
2) A variação de linfócitos T CD8
+
 e CD45
+
/mm
2 
em biópsias de glândulas salivares 
menores sinalizam o diagnóstico de DECHc em fígado. 
 
3) Comparando os  três grupos de pacientes (com DECHc, sem DECH e pacientes que 
nunca foram tratados pelo TCTH) concluímos quanto à: 
 Subpopulação de células inflamatórias - As GSM de pacientes com DECHc 
apresentam aumento do número de linfócitos T CD4
+
, CD8
+
, CD45RO
+
 e leucócitos 
CD45
+
/mm
2
. O fígado de pacientes com DECHc apresentou aumento do número de 
linfócitos T CD8
+
 e CD45RO
+
/mm
2
 por espaço porta. 
 Área acinar produtora de muco - A perda de ácinos funcionais das GSM se inicia 
com o condicionamento pré-transplante e pode ser uma causa da xerostomia 
observada nos pacientes pós-TCTH. 
 
4) Achados histológicos tanto em glândulas salivares menores quanto em fígado tem 
correlação com alterações clínicas e podem apresentar valor prognóstico para o paciente 
com DECHc.  
 A presença de degeneração dos ácinos com fibrose intersticial e dilatação ductal 
e/ou de infiltrado linfocítico ao redor dos ductos em glândulas salivares menores 
tem influencia no desenvolvimento da DECHc extensa. Não houve correlação dos 
achados histológicos em fígado com a forma extensa da DECHc. 
 O diagnóstico histopatológico da DECH em fígado tem correlação com alterações 
dos níveis séricos das enzimas hepáticas ALT, AST e FA. 
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 Os achados histológicos, “linfócitos ao redor e permeando os ductos” em glândulas 
salivares menores; “colestase canalicular” e a “presença de infiltrado inflamatório 
lobular composto por células polimorfonucleares além de linfócitos”, no fígado; 
demostraram ter valor prognóstico, em relação à sobrevida global do paciente.  
 
Apesar das atuais restrições quanto à indicação da biópsia de mucosa oral e 
GSM no diagnóstico da DECHc, os dados aqui apresentados mostram a importância das 
alterações histológicas em glândulas salivares menores na representação do acometimento 
da DECHc em outros órgãos com maior dificuldade de acesso, como o fígado. 
A validação dos dados aqui encontrados em um número maior de amostras, 
pode melhorar a compreensão da patogênese da DECHc oral e sua correlação com o 
envolvimento em outros órgãos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
REFERÊNCIAS
1
 
Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, et al. Hepatitic 
variant of graft-versus-host disease after donor lymphocyte infusion. Blood. 2002; 100: 
3903–7. 
Alborghetti MR, Correa MEP, Adam RL, Coracin FL, Souza CA, Cintra ML. Late effects 
of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med. 2005; 34: 
486-93. 
Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 
1992; 80: 2964–68. 
Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001; 411: 
385-9. 
Billingham RE. The biology of graft-versus-host reaction. Harvey Lect. 1966- 67; 62: 21-
78. 
Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. 
Nat Rev Cancer. 2004; 4: 371–80. 
Boer CC, Correa ME, Miranda EC, de Souza CA. Taste disorders and oral evaluation in 
patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010; 
45:705-11. 
Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 
2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de 
Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and 
International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 
106: 1495–500. 
                                                          
1
 De acordo com a norma da UNICAMP/FOP, baseadas na norma do International Commitee of Medical 
Journal Editors – Grupo de Vancouver. Abreviatura dos peródicos em conformidade com o Medline. 
66 
 
Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor 
necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality 
and acute graft-versus-host disease severity in HLA-matched sibling bone marrow 
transplants. Blood. 1999; 94: 3941–46. 
Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell 
transplantation. Curr Opin Immunol 2005; 17: 517–25. 
Duarte RF, Delgado J, Shaw BE, Wrench DJ, Ethell M, Patch D, et al. Histologic Features 
of the Liver Biopsy Predict the Clinical Outcome for Patients with Graft-versus-Host 
Disease of the Liver. Biol Blood Marrow Transplant. 2005; 11: 805-13. 
Epstein O, Thomas HC, Sherlock S. Primary Biliary Cirrhosis is a Dry Gland Syndrome 
with Features of Chronic Graft-versus-Host Disease. The Lancet. 1980; 12: 1166-8. 
Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667–74. 
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 
373:1550-61.  
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National 
Institutes of Health consensus development project on criteria for clinical trials in chronic 
graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood 
Marrow Transplant. 2005; 11: 945-56. 
Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J. Mismatches of minor 
histocompatibility antigens between HLA-identical donors and recipients and the 
development of graft-versus-host disease after  bone marrow transplantation. N Engl J Med 
1996; 334: 281–85. 
Harada M, Niho Y, Oka M. A comparison of glandular involvement between chronic graft-
versus-host disease and Sjögren syndrome. Int J Oral Maxillofac Surg 1996; 25: 298-307. 
67 
 
Hiroki A, Nakamura S, Shinohara M, Oka M. Significance of oral examination in chronic 
graft-versus-host disease. J Oral Pathol Med. 1994; 23: 209-215. 
Horn TD, Rest EB, Mirenski Y, Corio RL, Zahurak ML, Vogelsang GB. The significance 
of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. 
Arch Dermatol. 1995; 131: 964-5. 
Kida A, McDonald GB. Gastrointestinal, hepatobiliary, pancreatic, and iron-related 
diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin 
Hematol. 2012; 49: 43-58. 
Lauteuschlager L, Häyry P. (1981) Expression of the major histocompatibility complex 
antigens of differents liver cellular components in rat and man. Scan J Immunol. 14: 421-6. 
Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, et al. Relation of an 
interleukin-10 promoter polymorphism to graft-versus-host disease and survival after 
hematopoietic-cell transplantation. N Engl J Med. 2003; 349: 2201–10. 
Ma SY, Au WY, Ng IO, Lie AK, Leung AY, Liang R, et al. Hepatitic graft-versus-host 
disease after Hematopoietic stem cell transplantation: Clinicopathologic features and 
prognostic implication. Transplantation. 2004; 77: 1252–9. 
Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective 
analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 
1464–72. 
McDonald GB. Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 
Years On. Hepatology. 2010; 51: 1450-1460. 
McDonald, GB. Review article: management of hepatic disease following haematopoietic 
cell transplant. Aliment Pharmacol Ther. 2006; 24: 441–52. 
McDonald GB. Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 
Years On. Hepatology. 2010; 51: 1450-1460. 
68 
 
Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, et al. Antibody 
response to DBY minor histocompatibility antigen is induced after allogeneic stem cell 
transplantation and in healthy female donors. Blood. 2004; 103: 353-359. 
Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an 
enigma. Korean J Hematol. 2011; 46: 80-7.  
Nagler RM, Nagler A. The molecular basis of salivary gland involvement in graft--vs.--host 
disease. J Dent Res. 2004; 83:98-103. 
Orti-Raduan ESL, Nunes AJF, Oliveira DT, Lara VS, Taveira LAA. Quantitative analysis 
of Langerhans’ cells in oral chronic graft-vs.-host disease. J Oral Pathol Med. 2009; 38: 
132–7. 
Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, et al. Prognostic 
Factors of Chronic Graft-Versus-Host Disease After Allogeneic Blood Stem-Cell 
Transplantation. American Journal of Hematology. 2005; 78: 265-74. 
Pimentel VN, de Matos LS, Soares TC, Adam R, Metze K, Correa ME, et al. Perforin and 
granzyme B involvement in oral lesions of lichen planus and chronic GVHD. J Oral Pathol 
Med. 2010; 39:741-6.  
Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors 
contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, 
related hematopoietic stem cell transplants. Blood. 2004; 103: 347-352. 
Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal FOXP3+ 
regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107: 
1717–1723. 
Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y. Immunohistopathological 
study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med. 2006; 35: 33-6. 
69 
 
Saxena R, editor. Practical Hepatic Pathology: A Diagnostic Approach. Indianápolis: 
Elsevier Inc., 2011. 
Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am 2008; 52: 
79–109. 
Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007; 7: 340–52. 
Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of 
hepatic graft-versus-host disease after human marrow transplantation. Hepatology. 1988; 8: 
463–70. 
Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et al. Histopathologic 
diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 
II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006; 12:31-47. 
Soares AB, Faria PR, Magna LA, Correa ME, de Sousa CA, Almeida OP, et al. Chronic 
GVHD in minor salivary glands and oral mucosa: histopathology and 
immunohistochemical evaluation of 25 patients. J Oral Pathol Med. 2005; 34: 368-73. 
Socie G, Ritz J, Martin PJ. Current Challenges in Chronic Graft-versus-Host Disease. Biol 
Blood Marrow Transplant. 2010; 16: S146-S151. 
Soiffer RJ. Immune modulation and chronic graft-versus-host disease. Bone Marrow 
Transplantation. 2008; 42: S66–S69. 
Sprent J, Kishimoto H. The  thymus and central tolerance. Transplantation 2001; 72(Suppl 
8): S25-8. 
Srantopoulos S et al. High levels of B cell activating factor (BAFF) in patients with active 
chronic graft versus host disease. Clin Cancer Res. 2007; 13: 6107–14. 
70 
 
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, et al. Chronic graft-
versus-host disease in 52 patients: adverse natural course and successful treatment with 
combination immunosuppression. Blood. 1981; 57: 267–76. 
Tomás JF, Pinilla I, García-Buey ML, García A, Figuera A, Gómez-García de Soria VGG, 
et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical 
features and course in 61 patients. Bone Marrow Transplant. 2000; 26: 649–55. 
Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, et al. 
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. 
Blood. 2009; 114:702-8.  
Villar CC. Análise comparativa das características microscópicas da lesão liquenóide na 
GVHD crônica e no líquen plano de boca [Dissertação]. Piracicaba: UNICAMP/FOP; 
1999. 
Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-
host disease after bone marrow transplant. Ann Rev Med 2003; 54: 29–52. 
Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem 
cell transplantation. Annu Rev Immunol. 2007; 25: 139-70.  
Woo SB, Lee SJ, Schubert MM. Graft-vs-host Disease. Crit Rev Oral Biol Med. 1997; 8: 
201-1. 
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of 
FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. 
Blood. 2005; 106: 2903-2911. 
 
 
 
71 
 
 
72 
 
 
73 
 
 
